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RIASSUNTO 
L'interazione fra costituenti della parete intestinale e microflora commensale costituisce il 
principale artefice del mantenimento della barriera mucosale, della promozione dello sviluppo 
del tratto gastrointestinale (GI) e della modulazione di funzioni GI, quali motilità, secrezione, 
immunità mucosale e sensibilità viscerale. Un'alterata microflora è stata associata a disordini 
GI (malattie infiammatorie croniche intestinali, MICI o sindrome dell'intestino irritabile, IBS) 
mentre cambiamenti del microbiota intestinale durante le fasi dell’infanzia e dell’adolescenza, 
causati da infezioni o antibiotici, predispongono all'insorgenza di queste malattie. Inoltre, 
disfunzioni del SNE quali anomalie strutturali e/o variazioni nel contenuto di 
neurotrasmettitori, sono state associate all'insorgenza sia di MICI che di IBS. In questo 
contesto, giocano un ruolo chiave i recettori Toll-like (Toll-like receptors, TLRs), un sofisticato 
sistema di proteine che mediano la risposta infiammatoria contro agenti patogeni e attivano 
segnali benefici assicurando l'integrità tissutale in condizioni fisiologiche e patologiche. 
Polimorfismi nei geni che codificano i TLRs, inclusi il TLR2 ed il TLR4, sono stati associati a 
fenotipi diversi di malattia nei pazienti affetti da disordini GI. In questo studio sono state 
caratterizzate le alterazioni strutturali e funzionali del SNE murino indotte da i) anomalie nella 
composizione del microbiota, ii) cambiamenti nel segnale dell’immunità innata, mediato dai 
recettori TLR2 e 4 ed implicato nel riconoscimento di profili molecolari derivanti dalla 
microflora intestinale e iii) variazioni di espressione della proteina catecol-O-metiltransferasi 
(COMT), implicata nel turnover di neurotrasmettitori del SNE e del sistema nervoso centrale, 
come la dopamina e altre catecolamine. Tramite studi funzionali e strutturali in vitro 
utilizzando topi maschi C57BL/6J WT e TLR2-/- di pari età (21±5 giorni di età) è stata evidenziata 
la presenza di alterazioni significative della contrattilità intestinale e dell'architettura dell'ENS 
nei preparati di ileo provenienti dai topi geneticamente modificati. Una volta dimostrato che la 
delezione del gene codificante per il recettore TLR2 determinava anomalie strutturali e 
funzionali nel SNE, è stato valutato se il segnale mediato dal TLR2 derivasse da cellule 
immunocompetenti ematopoietiche oppure dalle diverse popolazioni cellulari esprimenti 
questo recettore e residenti nell’intestino, come i neuroni, la glia, le cellule muscolari lisce e le 
cellule endoteliali. Sono stati così generati topi chimera cioè portatori di cellule geneticamente 
distinte originate da topi 'donatori' WT e TLR2-/- di pari sesso ed età, quali: i) topi WT che 
hanno ricevuto il midollo osseo da topi WT donatori (WTWT), ii) topi WT che hanno ricevuto 
il midollo osseo da topi TLR2-/- donatori (TLR2-/-WT), iii) topi TLR2-/- che hanno ricevuto il 
midollo osseo da topi TLR2-/- donatori (TLR2-/-TLR2-/-), iv) topi TLR2-/- che hanno ricevuto il 
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midollo osseo da topi WT donatori (WTTLR2-/-). Esperimenti di contrattilità condotti nei topi 
chimera hanno dimostrato che le alterazioni della funzione neuromuscolare non sono 
dipendenti dal segnale TLR2 mediato dalle cellule ematopoietiche. Pertanto la valutazione dei 
topi deficienti per il TLR2 ha evidenziato il ruolo primario di questo recettore nel conservazione 
dell'integrità strutturale e funzionale del SNE. Al fine di approfondire il ruolo dell'asse TLR2-
microbiota nell’omeostasi del SNE e della muscolatura liscia enterica è stato messo a punto un 
modello animale di deplezione di microbiota intestinale attraverso la somministrazione 
intragastrica di 4 antibiotici, ampicillina (100 mg/kg), metronidazolo (100 mg/kg), neomicina 
(100 mg/kg) e vancomicina (50 mg/kg) due volte al giorno per 14 giorni a topi WT adolescenti 
(21±5 giorni di età; topi ABX). Da una prima valutazione il trattamento antibiotico ha 
determinato l’aumento delle dimensioni e del peso del cieco, caratteristica già osservata in 
topi adulti germ-free, ossia privi di microrganismi dalla nascita. Questa condizione, già 
evidenziata in soggetti affetti da IBS, sembra dovuta ad un ritardato svuotamento delle feci dal 
cieco ingrossato, ad indicare una compromissione della motilità dimostrata da un ritardato 
transito a livello del colon. Successivamente gli studi funzionali in vivo hanno rivelato una 
diminuzione significativa del transito gastrointestinale, accompagnata da alterazioni nella 
frequenza del pellet fecale e nel contenuto di acqua nelle feci. Tali risultati hanno evidenziato 
che il trattamento antibiotico determina una riduzione della motilità intestinale con possibili 
effetti a livello della barriera mucosale. In seguito, analisi immunoistochimiche su preparati di 
ileo provenienti da topi ABX hanno evidenziato anomalie nella distribuzione ed espressione 
della proteina marcatore pan-neuronale HuC/D, della proteina gliale strutturale GFAP (glial 
fibrillary acidic protein) e della subunità β della proteina S-100, marcatore gliale nucleare e 
citoplasmatico in grado di legare il calcio. Tali osservazioni sembrano confermare come la 
deplezione del microbiota intestinale possa influenzare l'integrità della rete neuronale e gliale 
enterica. Data l’importanza di una corretta composizione del microbiota commensale nel 
mantenimento della rete nervosa e del codice neurochimico del SNE è stata valutata la 
funzione intestinale in vitro mediante esperimenti di contrattilità utilizzando la tecnica 
dell'organo isolato su segmenti di ileo provenienti da topi CNTR e ABX. Queste analisi hanno 
evidenziato anomalie nell’attività contrattile neuromuscolare associate dopo trattamento 
antibiotico sottolineando l’importanza di una corretta composizione del microbiota nel 
mantenimento dell’attività motoria enterica. 
In parallelo, è stato ulteriormente dimostrato il ruolo primario del segnale mediato dal TLR2 
nel controllo dell’attività neuromuscolare, saggiando l’effetto del Pam3CSK4, ligando del TLR2, 
sulla disfunzione contrattile indotta dalla terapia antibiotica. La somministrazione di Pam3CSK4 
per via intraperitoneale, durante la seconda settimana di trattamento antibatterico ha 
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prevenuto l’entità del danno motorio intestinale, a sostegno della presenza di un dialogo tra il 
microbiota ed TLR2, fondamentale per la modulazione della funzione neuromuscolare. Per 
evidenziare l'importanza dell'asse microbiota-TLR2-SNE nel mantenimento della funzione 
intestinale e nello sviluppo del SNE è stato somministrato l'OxPAPC, inibitore dei segnali 
mediati sia da TLR2 che da TLR4, a topi WT adolescenti per via sottocutanea per 7 giorni 
consecutivi. Il trattamento con OXPAPC ha causato un’alterazione significativa della risposta 
neuromuscolare sia recettore-mediata che non nei topi trattati rispetto al controllo, già 
evidenziata in topi deficienti per il recettore TLR2, confermando l’importanza del segnale 
mediato da tali recettori nell'assicurare l’integrità funzionale e strutturale del SNE durante 
l'adolescenza. In parallelo sono state studiate le vie di neurotrasmissione, coinvolte nella 
sensibilità viscerale, nel modello animale di deplezione della microflora, analizzando 
l’espressione genica di GluN1, subunità funzionale del recettore NMDA del glutammato. E’ 
stato osservato un incremento dei livelli di mRNA di GluN1 nel plesso mienterico dei preparati 
di ileo provenienti dai topi ABX, evidenziando gli effetti di alterazioni della composizione del 
microbiota intestinale sulla sensibilità viscerale. 
Infine è stato approfondito il ruolo dell’asse ‘cervello-intestino’ attraverso la valutazione 
strutturale e funzionale del SNE in un modello animale di malattie psichiatriche, caratterizzato 
dalla riduzione genica di COMT, enzima responsabile della degradazione delle catecolamine. In 
animali di sesso femminile è stato dimostrato che gli aumentati livelli di catecolamine, dovuti 
alla riduzione genica di COMT, determinano alti livelli di NO e sofferenza neuronale con 
conseguente accelerato transito GI e sensibilità viscerale, a confermare il ruolo primario di 
polimorfismi funzionali di COMT in donne affette da IBS. 
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ABSTRACT 
The interaction between cellular constituents of gastrointestinal (GI) tract and commensal 
microflora is essential for the maintenance of mucosal barrier, promotion of the development 
of the GI system and modulation of enteric functions such as motility, secretion, mucosal 
immunity and visceral sensitivity. Alterations in the composition of the gut microflora have 
been associated to several GI disorders (e.g. inflammatory bowel disease, IBD, and irritable 
bowel syndrome, IBS) while changes in intestinal microbiota during infancy and adolescence, 
caused by infection or antibiotic therapy, appear to predispose to the onset of these diseases. 
Furthermore, dysfunctions of the enteric nervous system (ENS) such structural abnormalities 
and/or changes in the content of neurotransmitters, have been associated with the onset of 
IBD and IBS. In this context, a sophisticated system of proteins, so-called Toll-like receptors 
(TLRs), plays a key role in mediating the inflammatory response against pathogens and triggers 
beneficial signals to ensure tissue integrity under physiological and pathological conditions. 
Polymorphisms in genes encoding TLRs, including TLR2 or TLR4, have been associated with 
different phenotypes of disease extent and severity in patients with GI disorders. In this study 
we characterized structural and functional alterations of murine ENS induced by: i) anomalies 
in the composition of the microbiota, ii) changes in innate immunity response, mediated by 
TLR2 and/or TLR4 following recognition of gut commensal microflora, iii) alterations in the 
expression of the protein catechol-O-methyltransferase (COMT), involved in the turnover of 
several neurotransmitters present in both the ENS and the central nervous system, such as 
dopamine and other catecholamines. Functional and structural studies in male mice C57BL/6J 
WT and TLR2-/- (21 ± 5 days old) highlighted the presence of significant alterations of intestinal 
contractility and ENS architecture in ileal preparations of genetically modified mice. Once 
demonstrated that the deletion of the gene encoding for TLR2 determines ENS structural and 
functional abnormalities, it was examined whether TLR2-mediated functional anomalies were 
hematopoietic cell-independent. Therefore, bone marrow chimeric mice were generated and 
experimental transfers were as follows: WT donors into WT recipients (WT→WT), WT donors 
into TLR2-/- recipients (WT→ TLR2-/-), TLR2-/- donors into TLR2-/- recipients (TLR2-/-→ TLR2-/-), 
and TLR2-/- donors into WT recipients (TLR2-/-→ WT). Contractility experiments conducted in 
bone marrow chimeric mice evidenced that the structure and function of ENS were similar in 
WT mice given either WT or TLR2−/− bone marrow, indicating that TLR2 signaling in 
nonhematopoietic cells is a main contributor to ENS health. To investigate the role of the TLR2-
microbiota axis in the homeostasis of ENS and enteric smooth muscle we depleted gut 
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microbiota by intragastric administration of a cocktail of broad spectrum antibiotics (50 mg/kg 
vancomycin, 100 mg/kg neomycin, 100 mg/kg metronidazol and 100 mg/kg ampicillin) twice a 
day for 14 days in adolescent mice (aged 21 ± 5, ABX). Mice resulted to be successfully 
depleted after antibiotic treatment and displayed significantly smaller spleens and enlarged 
ceca, macroscopically phenocopying germ-free mice. This condition, already highlighted in IBS 
subjects, appears to be due to a delayed emptying of feces from enlarged cecum, due to 
impaired motility. Functional studies in ABX mice revealed a significant decrease in 
gastrointestinal transit, accompanied by alterations in the rate of fecal pellet expulsion and 
stool water content, to suggest that continuous presence of microbial stimuli is required to 
control intestinal motility and potentially mucosal barrier permeability. Immunohistochemical 
analysis of ileal preparations from ABX mice showed abnormalities in the distribution and 
expression of the the pan-neuronal marker HuC/D, the glial structural protein GFAP (glial 
fibrillary acidic protein) and the cytoplasmatic and nuclear glial calcium-binding protein S100β. 
Overall these observations highlight the primary role of commensal microbiota in the 
preservation of the structural integrity of the enteric neuronal and glial network. Given the 
importance of proper composition of commensal microbiota in the maintenance of neuronal 
network and neurochemical coding of the ENS intestinal contractility was evaluated in isolated 
ileal segments from control and ABX mice. These analyses evidenced impaired neuromuscular 
function associated to antibiotic treatment to further underline that proper neuromuscular 
function relies on a correct composition of gut microbiota.  
The primary role of TLR2 signaling in controlling gut motor function was further confirmed by 
testing the effect of TLR2 engagement by Pam3-CSK4 (a TLR2/TLR1 agonist) in ABX mice. 
Intraperitoneal supplementation with Pam3CSK4, during the second week of antibiotic 
treatment, partially corrected these anomalies in ENS structure and intestinal contraction, 
supporting the presence of a dialogue between commensal microbiota and TLR2, essential for 
the modulation of neuromuscular function. To highlight the key role of gut microbiota−TLR2-
ENS axis in maintaining intestinal function and development of the ENS, male C57Bl/6 mice (2 
weeks old) were daily treated subcutaneously with OxPAPC (a TLR2 and TLR4 inhibitor) for 7 
days. In vivo inhibition of both TLR2 and TLR4 determined a significant alteration of receptor 
and non-receptor-mediated neuromuscular responses, in a manner similar to that found in 
TLR2-deficient mice, providing evidence that TLR2 and TLR4 signaling is essential in ensuring 
the structural and functional integrity of the SNE during adolescence. Then, we investigate 
changes in gene expression of GluN1 subunit of N-Methyl-D-Aspartate (NMDA) receptor of the 
neurotransmitter glutamate in the myenteric plexus of ileal preparations from control and ABX 
mice. Antibiotic-mediated depletion of commensal microflora determined increased mRNA 
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levels of GluN1, suggesting that commensal microbiota is involved in modulating visceral 
sensitivity. 
Finally, the role of brain-gut axis in ENS homeostasis was assessed in an animal model of 
psychiatric disease, characterized by the genetic reduction of catechol-o-methyltransferase 
(COMT), an enzyme responsible for the degradation of catecholamines. In female animals 
genetic-driven COMT defective activity determined increased levels of NO associated to 
altered ENS architecture, neurochemical coding and visceral sensitivity. We cannot exclude 
that such changes may be involved in the pathogenesis of IBS in female patients, underlining a 
potential link with psychiatric disorders. 
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1. INTRODUCTION 
1.1 The Enteric Nervous System 
The digestive tract is unique among internal organs because it is exposed to a large variety of 
physical and chemical stimuli from the external environment in the form of ingested food. 
Therefore, the intestine has developed a rich repertoire of coordinated movements of its 
muscular apparatus to ensure the appropriate mixing and propulsion of contents during 
digestion, absorption, and excretion (Costa et al., 2000). An important arbiter of these 
processes is the enteric nervous system (ENS), a network of neurons and glial cells within the 
wall of the bowel that controls most aspects of intestinal function (Lake and Heuckeroth, 
2013). The ENS is located in the walls of the entire gastrointestinal tract from the esophagus to 
the anus and associated glands (salivary glands and the pancreas) and the gallbladder. 
Originally, the ENS was thought to be part of the autonomic component of the peripheral 
nervous system, and its neurons located in the gut wall were considered to be 
parasympathetic postganglionic neurons (Goyal and Hirano, 1996). The hypothesis of ‘little 
brain’ in the gut arised in the 1899, when the physiologists W.M Bayliss and E.H. Starling 
proposed the existence of enteric reflex pathways by means of the classic approach, i.e. 
inducing specific and localized stimuli and recording the reflex-like response. They 
demonstrated that intestinal contractions were coordinated by short ascending excitatory 
pathways and longer descending inhibitory pathways where majority of enteric neurons did 
not interact directly with the parasympathetic axons of the central nervous system (CNS) 
(Bayliss and Starling, 1899; Goyal and Hirano, 1996). These findings rised the hypothesis, so 
called “the law of the intestine”, which is now known as the peristaltic reflex. Further 
evaluations of the functional and chemical diversity of enteric neurons revealed that the ENS is 
closely similar to the CNS (Furness, 2000). The ENS contains more than 100 million neurons; 
approximately the number of neurons residing in the spinal cord (Furness and Costa, 1987). 
Therefore, in these late years the ENS has been assumed as a separate portion of the CNS with 
which it is in continuous communication through sympathetic and parasympathetic afferent 
and efferent neurons. On the other hand, the CNS is connected with the enteric neurons 
throughout the central autonomic neural network. Through these bidirectional connections 
the ENS provides neural control of all functions of the gastrointestinal tract (Goyal and Hirano, 
1996). 
The ENS is endowed with a wide array of restorative, maintenance and adaptive functions. 
Enteric reflex circuits detect the physiological condition of the gastrointestinal tract, integrate 
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information about its state, and provide outputs to control gut movements, fluid exchange 
between the gut and its lumen, epithelial permeability and local blood flow (Gershon, 2005; 
Furness, 2006). Enteric neurons also interact with the immune and endocrine systems of the 
gut and all of these functions contribute to the maintenance of the integrity of the intestinal 
epithelial barrier (Mach, 2004; Furness, 2006; Savidge et al., 2007).  
The importance of the ENS is highlighted by the varied range of enteric neuropathies that are 
triggered as a result of a failure in one or more of its components. These neuropathies have 
been grouped as congenital or developmental neuropathies (e.g. Hirschsprung disease), 
sporadic and acquired neuropathies (e.g. Chagas disease or irritable bowel syndrome, IBS), 
neuropathies associated with other disease states (which can be secondary to the other 
disorder, such as diabetic gastroparesis and other diabetes-related motility disorders), and 
iatrogenic or drug-induced neuropathies (e.g. postoperative ileus) and those associated with 
intestinal transplantation, such as neuropathy following ischemia and reperfusion injury 
(Furness, 2012). 
Anatomy of ENS 
The ENS is composed of small aggregations of nerve cells, enteric ganglia, the neural 
connections between these ganglia, and nerve fibers that supply effector tissues, including the 
muscle of the gut wall, the epithelial lining, intrinsic blood vessels, GI and pancreatic endocrine 
cells (Furness, 2012). The nerve-cell bodies are grouped into small ganglia which are connected 
by bundles of nerve processes to form the two major plexuses, so-called the myenteric (or 
Auerbach’s) plexus and the submucous (or Meissner’s) plexus (Figure 1.1). A few small ganglia 
occur in the mucosa, close to the muscularis mucosae (mucous plexus) (Hansen, 2003a). 
The myenteric plexus is positioned between the outer longitudinal and circular muscle layers, 
where forms a continuous network of ganglia and connecting axon bundles that extends from 
the upper esophagus to the internal anal sphincter (Furness, 2012). It primarily provides motor 
innervation to the two muscle layers and secreto-motor innervation to the mucosa. There are 
numerous projections from the myenteric plexus to the submucosal ganglia and to enteric 
ganglia of the gallbladder and pancreas (Kirchgessner and Gershon; 1990). Moreover, a 
substantial number of projections from the myenteric neurons are connected to the 
sympathetic ganglia (Goyal and Hirano, 1996; Hansen, 2003a) (Figure 1.1). The myenteric 
plexus shows a high density of neurons compared to the submucous plexus with an average 
ratio of the sensory, interneurons and motor neurons of 2:1:1, respectively (Costa et al., 2000; 
Hansen, 2003a). 
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The submucous plexus is located in the submucosa and in large mammals; it consists of more 
than one layer: an inner network located at the serosal side of the muscularis mucosae 
(Meissner’s plexus) and an outer (Schabadasch’s) plexus adjacent to the luminal side of the 
circular muscle layer. Moreover, in the human intestine, a third intermediate plexus lies 
between Meissner’s and Schabadasch’s plexus. Non-ganglionated plexuses also supply all the 
layers of the gut (Costa et al. 2000; Furness 2000; Hansen, 2003a). Submucosal ganglia and 
connecting fiber bundles form plexuses in the small and large intestines, but these ganglia are 
extremely rare in the stomach and esophagus (Furness, 2012) (Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Anatomy of ENS. Panel A: In the small and large intestines, the nerve cells are contained in 
ganglia of the myenteric plexus (MP) between the longitudinal (LM) and curcular muscle (CM) layers and 
in ganglia within the submucosa (SMuc), depicted in tranverse section through the gut wall. The ganglia 
and fibers in the submucosa form inner and outer submucosal plexus (SMP). Panel B: The distribution of 
ganglia along the gastrointestinal tract. Panel C. Neuromuscular layers along the small and large 
intestines (modified from Furness, 2012). 
Classification of enteric neurons 
The ENS is composed of a large number of enteric neurons that can be identified according to 
their location, neurochemistry, shape, projections, proportions, connections, and function 
(Costa et al., 2000; Furness, 2012). 
Sensory neurons 
There are many types of sensory neurons in the gut. The sensory neurons are represented by 
an extrinsic dense network of vagal and spinal afferents neurons with their cell bodies outside 
the gut wall and by intrinsic primary afferent neurons [IPANs, also termed enteric primary 
afferent neurons (EPANs)] with their cell bodies within the gut wall, in both myenteric and 
submucosal ganglia (Furness, 2000; Hansen 2003b). They respond to luminal chemical stimuli, 
to mechanical deformation of the mucosa, and to radial stretch and muscle tension. Together 
A B C 
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with endocrine and immune cells, IPANs form a functional network of surveillance. A 
bidirectional communications exists between intrinsic neurons and extrinsic afferent neurons 
(Holzer 2002). Whereas IPANs are essential for the neuronal control of the digestion, extrinsic 
afferent neurons provide information to the brain about processes that are relevant to energy 
and fluid homoeostasis together with the sensation of discomfort and pain (Holzer 2002; 
Hansen 2003b). IPANs represent about 30% of myenteric neurons and 14% of submucosal 
neurons, and they display a distinct Dogiel type II shape and have a long after-
hyperpolarization following action potentials (Costa et al., 2000).  
The class of sensory neurons also includes the mechano-, chemo- and thermoreceptors. 
Mechanoreceptors are activated by distension and generate tonic muscle contractions, and if 
distension is maintained, they respond by generating peristaltic activity. These 
mechanoreceptors are low-threshold nociceptors. Conversely, high-threshold afferents are 
thought to be the sensory analogues of pain (Furness et al. 2000; Kirkup et al. 2001). Acute 
visceral abdominal pain seems to emerge from activation, whereas chronic forms of visceral 
pain appears to result from peripheral sensitization of the high-threshold nociceptive fibers. 
The high-threshold mechanoreceptors normally remain sleeping and silent, but they can be 
awakened under such conditions as injury or inflammation. The silent nociceptors become 
sensitized by second order neurons (interneurons and motor neurons) via both slow and fast 
excitatory postsynaptic potentials (Furness et al., 2000; Kirkup et al. 2001).  
Sensory nerves express a variety of membrane receptors, responsible of modulating their 
activity. Some receptors (e.g. for substance P, calcitonin gene-related peptide, and vasoactive 
intestinal polypeptide, VIP) are involved in the normal sensory neurotransmission, whereas 
molecules derived from multiple cellular sources during ischemia, injury or inflammation 
activate others. Key agents in visceral abdominal hypersensitivity after tissue damage and 
inflammation are bradykinin, prostaglandins, leukotrienes, interleukin-1β, tumor necrosis 
factor α, 5-HT, adenosine triphosphate (ATP), glutamate, pituitary adenylate cyclase-activating 
polypeptide (PACAP), and adenosine. The mechanisms involved in gastrointestinal sensation 
include direct activation (e.g. opening of ion channels), sensitization, and alteration of the 
mediators of the afferent nerve. As such, receptor antagonists for these substances will be 
useful therapeutically to treat gastrointestinal hypersensitivity in acute and chronic 
inflammatory conditions. For example, opioid agonists selective for the mesenteric µ-receptors 
on vagal afferents are promising as visceral antinociceptive drugs (Eastwood and Grundy 2000; 
Kirkup et al. 2001; Yiangou et al. 2001).  
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Interneurons 
Interneurons form multisynaptic pathways in the length of the gut tube controlling the 
distances along the intestine where peristaltic waves are propagated. They are interposed 
between the primary afferent neurons and the motor or secretomotor neurons. Interneurons 
are both after-hyperpolarization and usually Dogiel type II neurons (Costa et al., 2000). 
Interneurons involved in motor reflexes are directed orally or anally and are designated as 
ascending or descending, respectively (Goyal and Hirano, 1996). The ascending interneurons 
are mainly cholinergic, whereas the descending ones, which are the majority, have a complex 
chemical coding including acetylcholine (Ach), nitric oxide (NO), VIP, 5-HT, and somatostatin. 
Interneurons which contain and release ACh/NO/VIP/somatostatin are involved in local 
motility reflexes, while ACh/5-HT neuros are involved in the local secretomotor reflexes. Two 
non-cholinergic, fast excitatory postsynaptic potentials, one mediated by ATP and the other by 
5-HT, mediate interneuronal transmission (Furness 2000; Hansen, 2003b). The dual projection 
of these interneurons to both myenteric and submucous ganglia represents the functional link 
between motor, secretory, and vasomotor pathways (Costa et al., 2000). 
Motor Neurons 
There are three broad types: muscle motor neurons, secretomotor or vasodilator neurons and 
neurons innervating enteroendocrine cells. Motor neurons are Dogiel type I and synaptic-type 
neurons. 
Muscle motor neurons  
Muscle motor neurons innervate the longitudinal and circular muscles and the muscularis 
mucosae throughout the digestive tract. The muscle motor neurons are either excitatory or 
inhibitory and, thus, release neurotransmitters provoking muscle contractions or relaxation). 
For the excitatory neurons, transmission is predominantly sustained by muscarinic cholinergic 
(ACh) and tachykinergic (substance P and neurokinin A) signaling. They act directly on smooth 
muscle and possibly indirectly via the network of interstitial cells in the deep muscular plexus 
(Costa et al., 2000). Regarding the inhibitory neurons, responsible of most of the descending 
accommodating inhibitory reflexes, the neuromediators released are NO, VIP, ATP, and 
possibly PACAP, gamma-aminobutyric acid (GABA), neuropeptide Y and carbon monoxide. The 
inhibitory neurons are normally switched off in the aboral direction, resulting in contractile 
activity that propagates from the esophagus to the distal part of intestine. In a situation of 
vomit, the opposite takes place. Loss or malfunction of inhibitory motor neurons underlies 
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several forms of chronic idiopathic constipation and esophageal sphincteral achalasia (Wood 
et al. 1999; Hansen 2003b). 
 
Secretomotor and vasomotor neurons 
Secretomotor and vasomotor (vasodilatator) neurons control secretions and blood flow, 
respectively. There are two main types of intestinal secretomotor neurons, cholinergic and 
non-cholinergic. ACh released from the cholinergic neurons acts on muscarinic receptors on 
the mucosal epithelium. The non-cholinergic neurons appear to mediate most of the local 
reflex responses and utilize VIP as a neurotransmitter. The delicate balance of epithelial 
transport processes (mainly secretions) and blood flow is accomplished by the intrinsic 
secretomotor neurons through local reflex circuits. These reflexes are under extrinsic 
modulation, primarily via the sympathetic transmission (Furness 2000; Hansen, 2003b). 
Neurons with a similar function and neurochemistry are also present in the submucous 
ganglia. Some of the VIP submucous neurons also project to the myenteric ganglia and may 
represent the basis for a functional connection between secretion and motility (Costa et al., 
2000). 
Enteric glial cells  
The ENS is composed mainly by neurons and enteric glial cells (ECGs), which are in number 
substantially larger than neurons. ECGs are usually small cells with highly irregular, stellate-
shaped body, associated to neuronal cell bodies in enteric ganglia in an intimate physical 
connection, highly reminiscent of the relationship between astrocytes and neurons in the CNS 
(Figure 1.2) (Gulbransen and Sharkey, 2012). ECGs also show connections with enteric nerve 
fiber bundles, which are similar to peripheral Schwann cells, but differ from these by the 
function (Lomax et al., 2005; Bassotti et al., 2007). 
All populations of enteric glia originate from a common pool of neural-crest-derived 
progenitors (Laranjeira and Pachnis, 2009) however, each population of ECGs residing in 
microenvironmental compartments of the gut wall represents a morphologically and 
functionally distinct subtype of enteric glia (Gulbransen and Sharkey, 2012). 
The ECGs ‘type I’ or ‘protoplasmic’ display star-shaped cells with short, irregularly branched 
processes resembling protoplasmic astrocytes of the CNS and closely embrace neuronal cell 
bodies and fibres within myenteric and submucosal ganglia (intraganglionic ECGs). Enteric glia 
‘type II’ represents the elongated glial cells within interganglionic fibre tracts, which are similar 
to fibrous astrocytes of the white matter in the CNS. The subepithelial glia consists of several 
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long branches that reach the mucosal epithelial cells, and thus could be grouped as ‘mucosal’ 
or ‘type III’ ECGs. The fourth type of enteric gliocytes are distributed between smooth muscle 
cells, running with neuronal fibres in the musculature, thus these cells are ‘intramuscular’ or 
‘type IV’ ECGs (Hanani and Reichenbach, 1994)(Figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Subpopulations of enteric glia. Panel A: Several subpopulations of enteric glia located within 
the gut wall with different proposed physiological functions and signaling mechanisms. Panel B: Mucosal 
enteric glia lie in the mucosa directly beneath the epithelial cells. Panel C: Intraganglionic glia surround 
neurons (blue) within the enteric nerve plexuses (submucosal and myenteric plexus). Panel D: 
Intramuscular glia are associated with enteric nerve fibers innervating the smooth muscle coats (circular 
muscle and longitudinal muscle) (modified from Gulbransen and Sharkey, 2012).  
 
ECGs resemble astrocytes in several ways, including the expression of the intermediate 
filament glial fibrillary acidic protein (GFAP; Jessen and Mirsky, 1980) and the Ca2+ binding 
protein, S100β (Ferri et al., 1982). Moreover, the expression of the transcription factors SOX8, 
SOX9, and SOX10 has been demonstrated in early ECGs of developing mouse ENS (Hoff et al., 
2008). 
Since enteric glia share many phenotypical features with astrocytes, ECGs were thought for a 
long time to provide sustenance and mechanical support for neurons, acting as a ‘glue’ 
(Boesmans et al., 2013). However, in the last two decades, it is becoming increasingly clear 
that ECGs play a role in the regulation of synaptic transmission, in the maintenance of 
intestinal epithelial barrier function and in the communication between the nervous and 
immune systems (Savidge et al., 2007; Van Landeghem et al., 2009; Gulbransen and Sharkey, 
2012). ECGs can modulate enteric neural circuits in several ways, including terminating the 
actions of neurotransmitters from synapses (Fletcher et al., 2002; Braun et al., 2004; Lavoie et 
al., 2011), supplying neurons with neurotransmitter precursors (Nagahama et al., 2001) and by 
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producing neuroactive substances (Gulbransen and Sharkey, 2012). For instance, ECGs, but not 
neurons, appear to contain L-arginine immunoreactivity, suggesting that this NO precursor is 
provided to enteric neurons by glial cells (Nagahama et al., 2001). In the ENS, EGCs express the 
γ-amino butyric acid (GABA) reuptake transporter GAT-2, which suggests its participation in 
the clearance of the neurotransmitter from the synaptic cleft (Fletcher et al., 2002). 
Furthermore, the glutamine synthetase expression has been detected in ECGs, suggesting that 
these cells are involved in the maintenance of glutamatergic signalling (Jessen and Mirsky, 
1983). Recent evidences demonstrate that purines are the most ubiquitous mediators of 
enteric neuron-to-glia crosstalk. EGCs were shown to express an extracellular surface-bound 
ectonucleotidase triphosphate diphosphohydrolase 2 (NTPDase2) (Braun et al., 2004), which 
can be important in the regulation of extracellular ATP levels after release from activating 
neurons. Furthermore, neuronal released ATP can activate the glial P2 receptors in multiple 
experimental models (Gomes et al., 2009; Gulbransen and Sharkey, 2009). Besides the well 
documented ‘protective role’, EGCs are activated by means of inflammatory insults and may 
directly contribute to an inflammatory condition working as an antigen presenting cell-type 
promoting a variegate release of cytokines, such as interleukin-6 (IL-6) and IL-1β (Rühl et al., 
2001; Neunlist et al., 2008; Murakami et al., 2009). Furthermore, ECGs may act as “receptors” 
for cytokines, produced by themselves (Cirillo et al., 2011b). In the CNS of higher vertebrates, 
astroglia can react to inflammatory insults with proliferation, increased cytokines secretion 
and overexpression of both GFAP and S100β proteins, a phenomenon known as reactive gliosis 
(Sofroniew and Vinters, 2010; Cirillo et al., 2011a). As a member of the cytoskeletal protein 
family, GFAP is thought to be important in modulating astrocyte motility and shape by 
providing structural stability to astrocytic processes (Eng et al., 2000). During astrogliosis, a 
rapid synthesis of GFAP occurs, which is demonstrated by the increase in protein content or by 
immunostaining with GFAP antibody (Eng et al., 2000). 
The S100β protein belongs to the S100 protein family that includes more than 20 EF-hand Ca2+-
Zn2+ binding proteins (Zimmer et al., 1995; Gonzalez-Martinez et al., 2003). In the brain, S100β 
exerts either trophic or toxic effects depending on its concentration in extracellular milieu 
(Cirillo et al., 2011a). Nanomolar concentrations of S100β promote neuronal survival, neurite 
outgrowth (Bramanti et al., 2010) and astrocytic proliferation (Zimmer et al., 2005). On the 
other hand, micromolar amounts of S100β protein have been observed in several 
neuropathologies such as Alzheimer’s disease and Down’s syndrome (Griffin et al., 1989; Van 
Eldik and Griffin, 1994). 
As the GI tract is continuously exposed to a variety of stimuli such as bacterial and food 
antigens, it is considered to be in a state of ongoing physiological inflammation (Lomax et al., 
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2005). Recent findings have demonstrated that S100β overexpression is associated with the 
onset and maintenance of inflammation in human gut (Cirillo et al., 2009). S100β upregulation, 
observed in celiac disease, is accompanied by enhanced iNOS protein expression and 
consequent release of NO, a crucial pro-inflammatory mediator in inflammatory bowel disease 
(IBD; Esposito et al., 2007; Cirillo et al., 2009). In humans, GFAP expression is altered in the 
mucosa of patients with IBD such as ulcerative colitis (UC) and Crohn’s disease (Cornet et al., 
2001).  
Role of ECGs in neurogenesis and neuron survival 
Embryonic development of the ENS involves rostro-caudal migration of cells derived from the 
neural crest- through the developing GI tract, with subsequent colonization and differentiation 
of these cells into neurons or glia (Le Douarin and Teillet, 1974). These multipotent precursor 
cells constitute a heterogeneous population that changes progressively as a function of 
developmental age and enviromental stimuli during migration or when are embedded in the 
gut wall (Gershon and Ratcliffe, 2006). The development of the ENS does not stop at birth. 
Final differentiation of enteric neurons still occurs after birth, when GFAP and SOX10-positive 
progenitor cells apparently downregulate their neurogenerative capacity (Joseph et al., 2011; 
Laranjeira et al., 2011). The maturation of enteric neurons into ganglia also persists in early 
postnatal life with ongoing adaptation of the three-dimensional architecture of enteric nerve 
fibers within the first 2 weeks of life (Schäfer et al., 1999; Faure et al., 2007; Collins et al., 
2014). Once developmental neurogenesis is complete, GFAP and SOX10-positive progenitor 
cells retain the ability to generate glia in the adult and a low level of gliogenesis occurs in the 
ENS during adulthood (Schäfer et al., 1999; Faure et al., 2007). 
An additional analogy between glia of the CNS and the ECGs of the ENS is the potential to exert 
neuroprotective effect through the production of neurotrophic factors such as the glial cell line 
derived neurotrophic factor (GDNF) and neurotrophin 3 (NT-3) (Anitha, et al., 2006). GDNF, an 
important neurotrophic factor for the ENS (Heuckeroth et al., 1998), acts with the co-receptor 
GDNF-receptor α (GFRα1) to activate the Ret tyrosine kinase receptor, stimulating both the 
MAPK and PI3K pathways (Takahashi, 2001). During development, GDNF is produced in the gut 
mesenchyme and its signalling through the proteins RET and GFRa1expressed on neural crest 
cells regulates the development of the ENS (Rodrigues et al., 2011). Several studies have 
previously shown that the proliferation, maturation, migration, and survival of the enteric 
neurons are critically dependent on the activity of the Ret tyrosine kinase receptor that is 
expressed not only in the developing but also in mature enteric neurons (Anitha et al., 2006; 
Gershon, 2010; Wang et al., 2010). Mutations in the human RET gene are responsible for 
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approximately 50% of familial cases of Hirschprung’s disease, a pathology characterized by an 
aganglionic terminal colon in children (Hickey et al., 2009). Moreover a reduction of GDNF 
availability contributes to changes in ENS architecture and function during diabetic neuropathy 
(Anitha et al., 2006). GDNF holds also the ability to promote neuronal survival under 
inflammatory conditions in the CNS (Mucke and Eddleston, 1993), that potentially could also 
exert on enteric neurons. There is evidence that GDNF production is up-regulated during 
colitis, plausibly for its potent anti-apoptotic effect on colonic epithelial cells which limits 
mucosal damage in the inflammed tissue (Steinkamp et al., 2003).  
1.2 The human intestinal microbiota 
Through the course of evolution, a complex microbial ecosystem has colonized the skin, oral 
cavity, respiratory, urogenital and GI tract of all mammals, including humans. The community 
of commensal microorganisms residing in or passing through the GI tract is referred to as the 
intestinal microbiota (Dethlefsen et al., 2006). The term microbiota is to be preferred to the 
older term bacterial flora, as the latter fails to account for the many nonbacterial elements 
(e.g. archea, viruses, and fungi) that now are known to be normal inhabitants of the gut 
(Willing et al., 2011). The human intestinal microbiota is composed of an astounding number 
and species of microorganisms that colonize symbiotically the human gut, comprising 
approximately 300 to 500 bacterial species, containing nearly 2 million genes (the so called 
microbiome). The human intestinal tract is colonized by about ten times more microbial cells 
than human body cells and thus it contain about 150 times more microbial genes than the 
human genome (Qin et al., 2010; Wopereis et al., 2014).  
Recent clinical studies demonstrated the great complexity of the human gut microbiota with 
hundreds of phylotypes, of which 80% still remain to be categorized (Zoetendal et al., 2008). 
Of the 10 bacterial phyla detected in the gut the Firmicutes, Bacteroidetes and Actinobacteria 
predominate, of which the Firmicutes is the most dominant and assorted phylum (Simren et 
al., 2013). 
The gut microbiota is differently distributed along the GI tract. Per gram of intestinal content, 
the microbial density increases from 101–104 microbial cells in the stomach and duodenum, 
104–108 cells in the jejunum and ileum, to 1010–1012 cells in the colon and faeces (Booijink et 
al., 2007; Dethlefsen et al., 2006; Gerritsen et al., 2011), indicating that the greater microbial 
amount of the human microbiota is located in the large intestine. The composition also differs, 
with predominantly Gram-positive bacteria in the upper Gl tract and mainly Gram-negative 
microorganisms and anaerobes in the colon, where the microbiota composition is totally 
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dominated by three phyla, Firmicutes, Bacteroidetes and Actinobacteria (Jones et al., 2009; 
Martinez et al., 2010). The composition of luminal intestinal microorganisms that populate the 
colon is quite uniform and faecal material seems to best represent the colonic microbiota 
composition (Eckburg et al., 2005). In contrast, there is only limited insight in the composition 
of the microbiota that resides in the small intestine. Especially the lower part of the small 
intestine, the ileum, has received until now minimal attention, mainly due to sampling 
difficulties caused by the inaccessibility of this region (Booijink et al., 2007). The composition 
of the small intestinal microbiota is largely influenced by a combination of gastric acid, bile and 
pancreatic juice that is secreted in the duodenum and generates a harsh environment for most 
microorganisms (Booijink et al., 2007; Gerritsen et al., 2011). Moreover, major differences 
exist between the microbiota present in the gut lumen and the microbiota embedded in the 
mucus layer of the GI tract (Schwiertz et al., 2010). 
A major challenge in the analysis of gut microbiota is the inability to culture most of the 
different residing species (Simren et al., 2013). Nevertheless, more than a decade ago, thanks 
to the advances in whole genome sequencing (WGS) and 16S rRNA pyrosequencing 
techniques, all culture-independent sequencing technologies, gut ecosystems have being 
started to be thoroughly studied in the native state. 16S rRNA gene sequencing is extensively 
used for phylogenetic reconstruction, nucleic acid-based detection, and quantification of 
microbial diversity whereas WGS additionally explores the functions of the metagenome. 
Interestingly, gut microbiota  retains a constant relative abundance at operational taxonomic 
unit (OTU) levels and altered microbial abundance has been associated with complex diseases 
such as symptomatic atherosclerosis, type 2 diabetes, obesity, inflammatory bowel disease 
and colorectal cancer (Andersson et al., 2008; Zoetendal et al., 2008; Mandal et al., 2015). 
The intestinal microbiota is coexisting in a homoeostatic relationship with the host, playing a 
role in metabolic, nutritional, physiological and immunological processes in the human body. It 
exerts important metabolic activities by extracting energy from otherwise indigestible dietary 
polysaccharides such as resistant starch and dietary fibers (Wopereis et al., 2014). These 
metabolic activities also lead to the production of important nutrients, such as short-chain 
fatty acids (SCFA), vitamins (e.g. vitamin K, vitamin B12 and folic acid) and amino acids, all 
essential nutrients for human beings (Albert et al., 1980; Conly et al., 1994). In addition, the 
intestinal microbiota participates in the defense against pathogens by the production of 
antimicrobial molecules. The gut microbiota has a primary role in the development and 
functionality of the innate and adaptive immune responses, but also in regulating GI sensory 
and motor functions and intestinal barrier homeostasis (Parkes et al., 2008; Gerritsen et al., 
2011). 
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Influence of gut microbiota on neurodevelopment 
Commensal microbes widely contribute to host phenotype and for this reason, mammals have 
been described as ‘superorganisms’, and terms such as ‘ecological development’ have been 
coined to indicate that development is process merging both host genetics and microbiota-
derived signals (Willing et al., 2011). Numerous studies in both invertebrates and vertebrates 
have established a clear connection between commensal microbes and gut physiology. The 
fruit fly Drosophila melanogaster has a relatively simple microbiome. However, comparisons 
between axenic and conventionally reared flies have shown multiple contributions of bacteria 
to host nutrition and physiology, including effects on the larval development rate (Storelli et 
al., 2011), adult lipid storage (Ridley et al., 2012), gut stem cell activity (Buchon et al., 2009), 
and mating preference (Broderick et al., 2014). The influence of the microbiota extends 
beyond the GI tract, playing a major role in the bidirectional communication between the gut 
and the CNS (Cryan and Dinan, 2012). Given the importance of gut microbiota in modulating 
health and neurodevelopment, the brain–gut axis has been extended to the microbiota–gut–
brain axis (Rhee et al., 2009; Collins et al., 2012), which represents a complex network of 
communication between the gut, the intestinal microbiota, and the brain modulating immune, 
ENS and CNS functions (Mayer, 2011; Collins et al., 2012; Borre et al., 2014). 
Prenatal period 
More than a century ago, Theodor Escherich postulated that the fetus is sterile into 
intrauterine environment (Escherich, 1886). It has only recently been revealed by molecular 
investigation that microbial exposure start before birth and the fetus appears to receive 
microorganisms from the mother during gestation (Jimenez et al., 2008; Satokari et al., 2009). 
The presence of bacterial species in the fetus (such as Escherichia coli, Enterococcus faecium, 
and Staphylococcus epidermidis) could result from the translocation of the mother’s gut 
bacteria via the bloodstream and placenta (Jimenez et al., 2008). The ENS development take 
place during pregnancy, when neural-crest derived cells migrate to the developing GI tract, as 
described in the previous section. In parallel, the brain formation in humans starts at 3–4 
weeks of gestation with a process event known as neurulation. Cortical neurogenesis occurs 
predominantly during in utero gestation, but can continue up to 2-5 years of age 
(Herschkowitz et al., 1997; Workman et al., 2013). Gliogenesis also begins during the in utero 
period where mature astrocytes are present in the brain by 15 weeks of gestation. 
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Furthermore, hippocampal neurogenesis peaks around 8–9 weeks and this can persist well 
into the postnatal period (Rakic and Nowakowski, 1981).  
Birth and weaning 
Postnatally, the microbial gut colonization is dependent on the birth delivery mode. Whereas 
vaginally born infants are colonized by fecal and vaginal bacteria from the mother, infants born 
by cesarean delivery are exposed to a different bacterial milieu closely related to that of the 
human skin and hospital environment (Biasucci et al., 2010; Dominguez-bello et al., 2010) 
(Figure 1.3).  
Early colonizers of the neonatal gut are mainly aerobes (such as staphylococci, streptococci 
and enterobacteria), while late colonizers are strict anaerobes (such as eubacteria and 
clostridia) as the total microbiota become more complex, more stable and converge to a 
common pattern (Stark and Lee, 1982; Palmer et al., 2007). 
During the first days of life, gut microbiota of the infant shows a low diversity and it is 
unstable, then the precise composition of the developing microbiota population is dependent 
on whether the infant is breast or formula fed (Thum et al., 2012) (Figure 1.3). The microbiota 
of the formula-fed infants appears to be more diverse than breastfed infants, whose 
microbiota has a more stable colonized pattern (Schwartz et al., 2012; Fan et al., 2014).  
Infants delivered by cesarean delivery are more likely to suffer from allergies, asthma, GI 
dysfunction, obesity, and diabetes later in life (Jakobsson et al., 2014). Moreover, breastfed 
infants demonstrate better neurodevelopmental outcomes and higher scores on intelligence 
tests (Kramer et al., 2008), but it is unclear whether these neurodevelopmental outcomes are 
a reflection of the microbiota composition. Thus, establishment of pioneer gut microbiota is a 
crucial stage in neonatal development and this is a critical period not only for ENS, but also for 
CNS development (Dominguez-Bello et al., 2010). In the CNS a considerable amount of 
morphological development, cell differentiation, and acquisition of function takes place during 
postnatal development. Synaptogenesis begins in earnest in the human brain after 
approximately post-birth (after the appearance of astrocytes) and synaptic density increases 
rapidly after birth to reach maximum levels by approximately 2 years of age (Huttenlocher, 
1979; Petanjek et al., 2011). 
Childhood and adolescence  
The gut microbiota colonization continues to develop throughout childhood and adolescence. 
The microbiota continue to evolve until adulthood with a gradual increase in Bacteroides spp., 
a decline in Lactobacillus spp. after the age of five and a decline in Bifidobacterium spp. in late 
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teenage (Hopkins et al., 2002; Balamurugan  et al., 2008). The next significant changes in the 
composition of the intestinal microbiota come with the introduction of solid food and 
weaning, since diet plays a crucial role in modulating microbiota composition (Borre et al., 
2014; Wopereis et al., 2014) (Figure 1.3). Several recent studies demonstrate a less diverse 
microbiota with sufficiently different microbial gut communities in adolescent children in 
comparison to adults (Agans et al., 2011; Ringel-Kulka et al., 2013). It appears that instability 
and immaturity of gut microbiota during childhood and adolescence could be susceptible to 
several factors, such as the use of antibiotics, stress, harmful environment, diet, and infections, 
which could result in dysbiosis and potentially have a negative impact on intestinal and mental 
health, leading to development of gut and brain disorders later in life (Hviid et al., 2011; 
Kronman et al., 2012; Borre et al., 2014; Desbonnet et al., 2015) (Figure 1.3). The effect of 
microbiota on the formation of neural circuits in the mammalian gut is highlighted by studies 
of germ-free mice that demonstrated that these animals have altered spontaneous circular 
muscle contractions and decreased nerve density in the jejunum and ileum (Collins et al., 
2014). In addition, germ-free mice showed reduced sensory neuron excitability, which was 
restored following colonization with normal microbiota (McVey Neufeld et al., 2013). In 
agreement with these observations, diet modifications leading to changes of microbiota 
composition resulted in significant alterations in gastrointestinal transit time (Kashyap et al., 
2013).  
Similar to ENS and gut microbiota development, brain maturation undergoes a crucial 
developmental phase during childhood and adolescence with various structural, 
neurochemical, and molecular changes occurring in response to genetic and environmental 
signals (Paus et al., 2008). A consequence of this major neuronal rewiring during adolescence 
is a high level of vulnerability to pathological insults ranging from stress to drugs, to abuse, and 
to dietary deficiencies, which leads to onset of numerous psychiatric disorders including 
schizophrenia, substance abuse, and mood disorders (Paus et al., 2008; Borre et al., 2014)  
Furthermore, adolescence is associated with hormonal changes that may result in differential 
susceptibility of men and women to various disorders. For example, autism and schizophrenia 
have a higher occurrence in males (Jacquemont et al., 2014), whereas mood disorders and IBS 
are more prevalent in females (Loftus et al., 2002; McHenry et al., 2014). 
Adulthood and Aging 
The gut microbiome evolves throughout the lifespan, but microbiota diversity and stability 
decline with aging (Claesson et al., 2011). Changes also occur in extreme old age when 
Bacteroides spp. decrease while Enterococcus spp. and Escherichia coli increase (Heuckeroth et 
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al., 1998; Mulligan, 2014). It has recently been shown that the microbial composition of aged 
individuals is influenced by their residential community, dietary regimen, and their health 
status (Claesson et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Factors influencing the development of the infant microbiota. In addition to mode of birth, 
mode of early nutrition, environment, other factors such as gestational age, genetics, and 
hospitalization, also influence the microbial composition of the infant. Infections and antibiotic usage 
influence the development of microbial landscape as does the selective transient enrichment by 
probiotics and prebiotics (modified from Borre et al., 2014). 
 
In addition to a range of medications used by the elderly, impaired digestive and motility 
functions, and thus malabsorption of nutrients, and a weakened immune system contribute to 
compromised diversity and stability of the gut microbiota composition (Biagi et al., 2013). The 
ENS is plastic and continues to undergo changes throughout life, as the gut grows and 
responds to dietary and other environmental factors. Thus the effects of the microbiota and 
the complex interactions between enteric ganglion cells, mucosal immune system and 
intestinal epithelium indicate that other factors may well influence aging of enteric neurons 
(Saffrey, 2013). The CNS development continues during adulthood. The brain reaches its 
maximal weight by approximately 20 years of age (Dekaban, 1978), while white matter volume 
continues to increase and the peak of myelination is observed at approximately 50 years of 
age (Sowell et al., 2003). Although adulthood does not appear to be a critical or vulnerable 
phase, it remains a period during which alterations in the microbiota can influence brain and 
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behavior. Therefore, maintaining a healthy gut microbiota and mental health is an important 
aspect in possible prevention or attenuation brain disorders associated with aging. 
 
1.3 Toll-like receptors 
All living organisms are constantly exposed to environmental microorganisms, thus they need 
to cope with their potential invasion into the body. The vertebrate immune response can be 
divided into innate and acquired immunity. The innate immune system is the first line of host 
defence against pathogens and is mediated by phagocytes including macrophages and 
dendritic cells (DCs; Akira et al., 2006). In fact, to control the infection during the first days, the 
organism, through innate immune system, modulates some important functions including 
opsonization, activation of complement, coagulation cascades, phagocytosis, activation of 
proinflammatory signaling cascades and apoptosis (Janssens and Beyaert, 2003). By contrast, 
acquired immune responses are slower processes, in the late phase of infection, which are 
mediated by T and B cells, both of which express highly diverse antigen receptors that are 
generated through DNA rearrangement and are thereby able to respond to a wide range of 
potential antigens and to generation of immunological memory (Akira et al., 2006). This highly 
sophisticated system of antigen detection is found only in vertebrates and has been the 
subject of considerable research. Far less attention has been directed towards innate 
immunity, as it has been regarded as a relatively nonspecific system, however is able to 
discriminate between self and a variety of pathogens and to present antigen to the cells 
involved in acquired immunity (Akira et al., 2006). Also the innate immune system has an 
important function in activation and shaping of the adaptive immune response through the 
induction and release of co-stimulatory molecules and cytokines (Medzhitov, 2007) (Figure 
1.4). In contrast to the clonotypic receptors, expressed by B and T lymphocytes, the innate 
immune system uses nonclonal sets of recognition molecules, called pattern recognition 
receptors (PRRs; Janssens and Beyaert, 2003) (Figure 1.4).  
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Figure 1.4. Activation of host-defence mechanisms (modified from Medzhitov, 2007). 
The Toll like receptors (TLRs) are one of the most important PRRs families. The discovery of the 
TLRs started with the identification of the receptor ‘Toll’, a protein expressed in Drosophila 
melanogaster and involved in controlling embryonic development (Akira and Takeda, 2004; 
Okun et al., 2011). Subsequent genetic studies have led to the discovery of genes important in 
the dorsal-ventral patterning of the embryo (i.e., the dorsal group of genes, including Toll, 
tube, pelle, cactus, the NF-B homolog dorsal, and seven genes upstream of Toll; Belvin and 
Anderson, 1996). Since NF-B is involved in mammalian immunity, gradually became evident 
the contribution of TLRs in the signaling pathways in regulating Drosophila embryonic 
development and activating the immune system (Wasserman, 1993). In 1995 Hultmark and 
colleagues first identified Toll-1 as an activator of the immune response in a Drosophila cell 
line. Around the same time, a human homolog of Toll was identified and mapped to 
chromosome 4p14 (Taguchi et al., 1996). Later on, an in vivo study in Drosophila demonstrated 
that the Toll signaling is involved also in the antifungal response (Lemaitre et al., 1996). In 1997 
the first mammalian TLR was described by the group of Medzhitov. Subsequently, five human 
TLRs have been characterized (Rock et al., 1998) that are involved only in controlling immune 
responses with no role in the development whereas the Drosophila Toll pathway is implicated 
both in immunity and developmental processes (Valanne et al., 2011). TLRs are type I 
transmembrane proteins responsible in the recognition of foreign pathogens referred to as 
pathogen-associated molecular patterns (PAMPs). PAMPs are well suited to innate immune 
recognition for three main reasons: i) they are invariant among microorganisms of a given 
class; ii) they are products of pathways that are unique to microorganisms, allowing 
discrimination between self and non-self molecules; iii) they have essential roles in microbial 
physiology, limiting the ability of the microorganisms to evade innate immune recognition 
through adaptive evolution of these molecules (Medzhitov, 2007). Bacterial PAMPs are often 
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components of the cell wall, such as lipopolysaccharide (LPS), peptidoglycan (PG), lipoteichoic 
acids (LTA) and cell-wall lipoproteins. An important fungal PAMP is beta-glucan, which is a 
component of fungal cell walls but also viral nucleic acids structures are recognized by TLRs. An 
important aspect of pattern recognition is that PRRs themselves do not distinguish between 
pathogenic microorganisms and symbiotic (non-pathogenic) microorganisms, because the 
receptor ligands are not unique to pathogens (Medzhitov, 2007). So far, 10 and 12 functional 
TLRs have been identified in humans and mice, respectively, with TLR1–TLR9 being conserved 
in both species. Mouse TLR10 is not functional for a retrovirus insertion, and TLR11, TLR12 and 
TLR13 have been lost from the human genome (Kawai and Akira, 2010) (Table 1.1). Studies in 
mice deficient in each single TLR type have demonstrated that every TLR has a distinct function 
in terms of PAMP recognition and activation of immune responses (Akira et al., 2006). 
TLR1, 2, 4 and 6 recognize lipid-based structures. TLR4 recognizes LPS from Gram-negative 
bacteria, which causes septic shock (Akira et al., 2006). TLR2 forms heterodimers with TLR1 
and TLR6 and in concert with TLR1 or TLR6 discriminates between the molecular patterns of 
triacyl and diacyl lipopeptide, respectively, which derived from Gram-positive bacteria, 
mycoplasma and mycobacteria (Kumar et al., 2009). TLR5 and 11 recognize protein ligands. 
TLR5 is expressed abundantly in intestinal CD11c-positive lamina propria cells where it senses 
bacterial flagellin (Uematsu and Akira, 2006). TLR3, 7, 8 and 9, being localized intracellularly, 
detect nucleic acids derived from viruses and bacteria. TLR3 was shown to recognize double 
stranded RNA (dsRNA) generally produced by many viruses during replication. TLR7 recognizes 
synthetic imidazoquinoline-like molecules, guanosine analogs such as loxoribine, single 
stranded RNA (ssRNA) derived from viruses and small interfering RNA (Akira et al., 2006) (Table 
1.1). TLRs are expressed on a variety of cells, including immune cells, such as macrophages, 
DCs, B cells, specific types of T cells, and also fibroblasts, epithelial cells and neurons. 
Expression of TLRs is not static but rather is modulated rapidly in response to pathogens, an 
array of cytokines and environmental stressors (Akira et al., 2006). Furthermore, TLRs may be 
expressed extracellularly or intracellularly. While certain TLRs (TLRs 1, 2, 4, 5, and 6) are 
expressed on the cell surface, others (TLRs 3, 7, 8, and 9) are found almost exclusively in 
intracellular compartments such as endosomes, and their ligands, mainly nucleic acids, require 
internalization to the endosome before receptor signaling is possible (Akira et al., 2006).  
The engagement of TLRs by microbial components triggers the activation of signaling cascades, 
leading to the induction of genes involved in antimicrobial host defense. TLRs are 
characterized by an ectodomain composed of leucine rich repeats (LRR) that are responsible 
for recognition of PAMPs and a cytoplasmic domain homologous to the cytoplasmic region of 
the IL-1 receptor, known as the TIR domain, which is required for downstream signalling 
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(Kawai and Akira, 2007).  
After ligand binding, TLRs dimerize and undergo conformational changes required for the 
recruitment of TIR-domain-containing adaptor molecules of the TLR (Akira et al., 2006). The 
adaptor molecules include myeloid differentiation factor 88 (MyD88), TIR-associated protein 
(TIRAP)/MyD88-adaptor-like (MAL), TIR-domain-containing adaptor protein-inducing IFN-b 
(TRIF)/TIR-domain-containing molecule 1 (TICAM1) and TRIF-related adaptor molecule (TRAM; 
Oshiumi et al., 2003; Yamamoto et al., 2002) (Figure 1.5). 
 
TLR Location of TLR PAMPs recognized by TLR Co-receptor (s) 
Signaling 
adaptor 
Transcription factor(s) 
Effector cytokines 
induced 
TLR1/2 
Plasma membrane 
(cell surface) 
Triacyl lipopeptides (Bacteria and 
Mycobacteria) 
Hetrodimer of 
TLR1/2 forms a 
functional receptor 
TIRAP, 
MyD88 
NFκB 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.) 
TLR2 
Plasma membrane 
(cell surface) 
Peptidoglycan (Gram-positive 
bacteria), LAM (Mycobacteria), 
Hemagglutinin (Measles virus), 
Phospholipomannan (Candida), 
Glycosylphosphophatidyl inositol 
mucin (Trypanosoma) 
CD36, RP105 
TIRAP, 
MyD88 
NFκB 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.) 
TLR3 Endosome 
ssRNA virus (WNV), dsRNA 
virus(Reovirus), RSV, MCMV  
TRIF 
NFκB,  
IRF3,7 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.), type I IFNs 
TLR4 
Plasma membrane 
(cell surface) 
LPS (Gram-negative bacteria), 
Mannan (Candida), 
Glycoinositolphospholipids 
(Trypanosoma), Envelope proteins 
(RSV and MMTV) 
MD2, CD14, LBP, 
RP105 
TIRAP, 
MyD88, 
TRAM and 
TRIF 
NFκB,  
IRF3,7 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.), type I IFNs 
TLR5 
Plasma membrane 
(cell surface) 
Flagellin (Flagellated bacteria) 
 
MyD88 NFκB 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.) 
TLR6/2 
Plasma membrane 
(cell surface) 
Diacyl lipopeptides (Mycoplasma), 
LTA (Streptococcus), Zymosan 
(Saccharomyces) 
Hetrodimer of 
TLR6/2 or dectin-1 
forms a functional 
receptor 
TIRAP, 
MyD88 
NFκB 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.) 
TLR7 Endosome ssRNA viruses (VSV, Influenza virus) 
 
MyD88 
NFκB,  
IRF7 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.), type I IFNs 
TLR8# Endosome ssRNA from RNA virus 
 
MyD88 
NFκB,  
IRF7 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.), type I IFNs 
TLR9 Endosome 
dsDNA viruses (HSV, MCMV), CpG 
motifs from bacteria and viruses, 
Hemozoin (Plasmodium) 
 
MyD88 
NFκB,  
IRF7 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.), type I IFNs 
TLR11⁎ 
Plasma membrane 
(cell surface) 
Uropathogenic bacteria, profillin-
like molecule (Toxoplasma gondii)  
MyD88 NFκB 
Inflammatory 
cytokines (TNF-α, IL-6 
etc.) 
Table 1.1 Descriptions of TLR location and characteristics (modified from Kumar et al., 2009). 
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Figure 1.5. TLR signaling in conventional dendritic cells, macrophages and plasmatoid dendritic cells 
(modified from Kumar et al., 2009).  
The differential responses mediated by distinct TLR ligands can be explained in part by the 
selective usage of these adaptor molecules. MyD88 and TRIF are responsible for the activation 
of distinct signaling pathways, leading to the production of pro-inflammatory cytokines and 
type I IFNs, respectively (Kumar et al., 2009). 
MyD88 is a universal adapter that activates inflammatory pathways; it is shared by all TLRs 
with the exception of TLR3. For the complexity of the pathway, the TLR signaling pathway is 
categorized into MyD88-dependent and TRIF-dependent pathways (Akira et al., 2006). Upon 
stimulation, MyD88 associated with the portion of TLRs recruits IL-1R associated kinase (IRAK), 
which leads to the activation of TNF receptor associated factor 6 (TRAF6) to promote 
stimulation of TAK1 which results in the activation of MAP kinase or NF-B through IKK 
complex, resulting in the induction of genes involved in inflammatory response (Akira et al., 
2006). Also TIRAP mediates the activation of MyD88-dependent pathway. While TRIF activates 
an alternative pathway to induce a production of inflammatory cytokines and type I 
interferons (INFs). TRIF interacts with receptor-interacting protein 1 (RIP1), through a MyD88-
independent way, determining the production of several cytokines (Kawai and Akira, 2007). 
The TRIF-dependent pathway induces INFs through IRF3 that is phosphorylated and activated 
by IKK-related kinase (TBK1 and IKKi) via TRAF3, a linker between TRIF and TBK1 (Kumar et al., 
2009). TLR9 and TLR7 mediated INFs secretion in a MyD88-dependent manner, in contrast to 
TLR3 and TLR4 that produce TRIF-dependent IFN response (Kumar et al., 2009) (Figure 1.5).  
TLRs play also a role in the cross-talk between the intestinal microbiota and the host, as they 
specifically recognize conserved microbial molecular structures, called microbe-associated 
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molecular patterns (MAMPs) (Martin et al., 2010). Any alterations of these interactions can 
lead to the development of several bowel disorders including inflammatory bowel disease 
(Gribar et al., 2008).  
TLR4 has been found to detect LPS, a major component of Gram-negative bacteria cell walls 
(Okun et al., 2011). The stimulation of TLR4 by LPS determines in the activation of MyD88-
dependent and MyD88-independent pathways, leading to the production of several 
inflammatory cytokines and IFN-beta, associated with the expression of IFN-inducible genes, 
(Akira and Takeda, 2004). Study performed by Anitha and colleagues (Anitha et al., 2012) 
focused on the role of TLR4 signaling in the colon, found that the TLR4 pathway is important 
for the survival of enteric neurons and for the maintenance of GI functions.  
TLR2 is expressed in a wide variety of cells and plays a major role in detecting a large variety of 
PAMPs, in particular derived by Gram-positive bacteria. TLR2 recognizes PG and LTA, which are 
present in the cell membrane of Gram-positive bacteria (Schwadner et al., 1999; Takeuchi et 
al., 1999). TLR2 interacts physically and functionally with TLR1 and TLR6, which appear to be 
involved in the discrimination of subtle changes in the lipid portion of lipoproteins (Ozinsky et 
al., 2000). The importance of TLR2 in the host defense against Gram-positive bacteria has been 
demonstrated using TLR2-deficient (TLR2−/−) mice, which have been found to be highly 
susceptible to challenge with Staphylococcus aureus or Streptococcus pneumoniae (Takeuchi et 
al., 2000; Echchannaoui et al., 2002). TLR2 appears also to have a crucial role in host defense 
against extracellular growing of Gram-positive bacteria (Takeda and Akira, 2004) and it seems 
to be a major player in gut homeostasis by exerting cytoprotective effects in intestinal 
epithelial cells. Indeed, the absence of TLR2 increases susceptibility to intestinal injury and 
inflammation (Cario et al., 2007). Polymorphisms in TLRs genes or in general a defective 
immune response, are involved in the initiation and perpetuation of chronic inflammation in 
inflammatory bowel diseases (IBD; Pierik et al., 2006).  
Apart from PAMPs/MAMPs-derived ligands, TLRs also sense endogenous molecules released 
from stressed or dying cells—termed damage- or danger-associated molecular patterns 
(DAMPs), mainly derived from tissue damaged by oxidative stress. For example, TLR4 
recognizes heat shock protein (Hsp) 60, Hsp 70 and fibrinogen and TLR2 recognizes Hsp 70, 
hyaluronan, and versican, as most recently shown (Kim et al., 2009). After recognition of 
DAMPs, TLRs activate and orchestrate several innate immune machineries, promoting 
apoptosis and shaping adaptive immune responses, but the deregulation of this response can 
lead to inflammatory collateral tissue damage and some forms of autoimmunity and 
autoinflammatory diseases (Land, 2015). 
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TLRs are also expressed in several residing cells of the CNS such as astrocytes, microglia, 
oligodendrocytes and neurons, and the regulation of their expression seems to be dynamic 
and associated with profoundly changes during aging (Letiembre et al., 2007). In the brain, 
TLRs can be activated not only after the invasion of pathogens but also in the absence of 
microbial infection (Zhang and Schluesener, 2006) and regulate neurogenesis through the 
release of growth factors (Rolls et al., 2007). Okun and colleagues suggested the existence of a 
paradigm in which exists an auto-regulation of the innate immune system in the CNS, which 
helps to prevent excessive inflammation during pathogen infections (Okun et al., 2009). 
Microglial cells are the “pivotal” players in the innate regulation of inflammatory responses in 
the CNS and, once activated bzy inflammatory stimuli, operate to maintain CNS integrity, 
however in case of massive and uncontrolled release of proinflammatory mediators, microglia 
may cause severe neuronal damage (Aravalli et al., 2007). Also it should be noted that changes 
in the permeability of blood-brain barrier (BBB) are crucial for the infiltration of antibodies and 
lymphocytes from the peripheral site, leading to the degeneration of the neuronal structure 
(Nguyen et al., 2002). In this case the condition is critical, because alterations of BBB are 
probably linked to increased vulnerability of CNS cells and excessive innate immune responses 
together with the production of cytokine, a condition known as excitotoxicity (Nguyen et al., 
2002). Alternatively, a peripheral challenge can generate a systemic inflammation with the 
secretion of molecules of innate immune system that are able to cross the BBB and damage 
the CNS (Yang et al., 2000). In fact some authors demonstrated that perturbed stability of the 
BBB is pesent in neurodegenerative disease such as Alzheimer’s disease, stroke and 
amyotrophic lateral sclerosis (Huber et al., 2001). This instability of the barrier is associated 
with a severe inflammation and overexpression of TLRs, and the dynamic expression of these 
receptors seem to be involved in the progression of neurodegenerative pathologies in both 
normal aging and age-related disease (Okun et al., 2009). 
1.4. Irritable Bowel Syndrome: a chronic functional gastrointestinal 
disorder  
Functional gastrointestinal disorders (FGIDs) are the most common GI motility disorders in the 
general population. The term "functional" is generally applied to disorders where the body's 
normal activities in terms of the movement of the intestines, the sensitivity of the nerves of 
the intestines, or the way in which the brain controls some of these functions are impaired 
(Drossman, 2006). Irritable Bowel Syndrome (IBS) is one of the main chronic FGID and is 
reported to occur in 10-20% of the general population in developed countries (Simsek, 2011). 
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Widespread symptoms associated with the IBS are abnormal defecation and abdominal pain, 
both of which may be exacerbate by emotional stress. Abnormal defecation can be diarrhea 
(IBS-D) or constipation (IBS-C), and a subgroup of IBS patients may alternate from one to the 
other over time (mixed IBS; IBS-M). Urgency to stool often accompanies the diarrheal-state, 
and patients with the constipation-predominant form of IBS report abdominal tension and the 
feeling of incomplete evacuation (Wood, 2002). IBS is the most common disorder seen by 
gastroenterologists and can be associated with significant emotional distress, impaired health-
related quality of life, disability, and high health care costs (Quigley, 2003). The prevalence of 
IBS within an industrialized community is between 10% and 25% (Jones and Lydeard, 1992; 
Agreus et al., 1995; Thompson et al., 2002; Husain et al., 2008). A recent meta-analysis study 
showed a pooled estimate of international IBS prevalence of 11.2% with variation by 
geographic region; the lowest occurring in South Asia (7.0%) and the highest in South America 
(21.0%) (Lovell and Ford, 2012). IBS is reported more frequently by women than men in 
Western countries, female–male odd ratio being 2:1 and seems to be more common in the 
ages between 20 and 40. Traditionally, IBS can affect people at any age, but it is not diagnosed 
in people after the age of 60, when organic diseases of the gut become more frequent 
(Garnett, 1999; Camilleri, 2001; Bennett and Thalley, 2002). The disorder cannot be explained 
by specific pathophysiologic mechanisms, since it is not associated with any structural finding 
or biological marker (Mach, 2004). However, the symptoms of IBS are related to combinations 
of several known physiological determinants such as abnormal motor reactivity, enhanced 
visceral hypersensitivity, altered mucosal immune and inflammatory functions (which includes 
changes in bacterial flora), and altered brain-ENS regulation, which is influenced by 
psychosocial and socio-cultural factors (Drossman, 2006; Ohman and Simren, 2010; Simren et 
al., 2013).  
Diagnosis of IBS 
The definition and classification of symptomatic manifestations of IBS is the result of careful 
evaluation by the clinical and scientific community for several decades. In order to standardize 
and define IBS and reduce unnecessary surgery, Manning and colleagues proposed six 
diagnostic criteria for discriminating patients with IBS from those with other organic diseases 
(Manning et al., 1978; Talley et al., 1990) (Table 1.2). Four symptoms have been found to be 
significantly more common in patients with IBS, which are visible abdominal distension, relief 
of abdominal pain with a bowel movement, more frequent bowel movements with the onset 
of abdominal pain and looser bowel movements with the onset of abdominal pain. Manning 
criteria were then developed through expert consensus to create the Rome criteria, of which 
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are known three versions: Rome I, II, and III (Thompson et al., 1999; Longstreth et al., 2006; 
Table 1.2).  
 
Manning 
(1978) 
Rome I (1989) Rome II (1999) Rome III (2006) 
2 or more of the 
following 
symptoms: 
Abdominal 
distension 
Pain relief with 
defecation 
Frequent stools 
with pain 
Looser stools with 
pain 
Passage of mucus 
Sensation of 
incomplete 
evacuation 
At least 3 months of 
continuous or recurrent 
abdominal pain: 
Relieved with defecation 
or 
Associated with change 
in stool consistency 
With at least 2 of the 
following on at least 25% 
of days: 
Altered stool frequency 
Altered stool form 
Altered stool passage 
Passage of mucus 
Bloating or abdominal 
distension 
At least 12 weeks in past 12 
months of continuous or 
recurrent abdominal pain or 
discomfort 
With at least 2 of the following: 
Relief with defecation 
Altered stool frequency 
Altered stool form 
Onset of symptoms more than 12 
months before diagnosis 
At least 3 days per month in past 
12 weeks of continuous or 
recurrent abdominal pain or 
discomfort 
With at least 2 of the following: 
Relief with defecation 
Altered stool frequency 
Altered stool form 
Onset of symptoms more than 6 
months before diagnosis 
Table 1.2. Comparison of the Manning and Rome diagnostic criteria frequently used for diagnosis of IBS 
(modified from Canavan et al., 2014). 
 
 
According to the most recent Rome III criteria, IBS, which belongs to the category C1 (bowel) of 
FGIDs, is more specifically defined as pain associated with change in bowel habit, and this is 
distinct from functional diarrhea (C4) characterized by loose stools and no pain, or functional 
bloating (C2) when there is no change in bowel habit. Each condition also has different 
diagnostic and treatment approaches (Drossman, 2006). The Rome scoring system is primarily 
a descriptive instrument of key value in the clinical management of IBS patients, however it 
may be not informative and poorly applicable to predict the molecular mechanisms and 
associated gene products that contribute to the different phenotypes (D’Amato, 2013). 
Pathophysiology of IBS 
IBS is defined as disorder with multifactorial etiology (Figure 1.6). Currently, the model for IBS 
incorporates several mechanisms, including visceral hypersensitivity, abnormal GI motility and 
secretion together with mucosal inflammation due to enteric infection, stress, food allergy and 
dysbiotic changes in gut microbiota (Daulatzai, 2014). The pathophysiology of IBS, still 
inadequately clear, is attributed to multilevel dysregulation of the nervous and intestinal 
system interactions (Ohman and Simrén, 2007). The brain-gut axis constitutes a bidirectional 
signaling pathway between the CNS and the GI tract that preserves the health of the body as a 
whole. This signaling pathway is regulated at multiple neural, hormonal and immunological 
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levels (Karling et al., 2007). Alterations presented in any of these levels (e.g. autonomic 
nervous system dysregulation, altered serotonin metabolism, mast cell activation) contribute 
to the presentation of the disorder (Gasbarrini et al., 2008; Kennedy et al., 2012) (Figure 1.6). 
 
 
 
 
 
 
 
 
Figure 1.6. Rome III criteria for the classification of IBS, and underlying predicted risk factors and 
pathogenetic mechanisms (modified from D’Amato, 2013) 
Abnormal GI Motility  
Disturbance of GI motility occurs in about 25–75% of patients with IBS (Drossman et al., 2002). 
Many studies identified abnormal patterns of contractile and electrical activity in the colon of 
patients with IBS. In D-IBS, patients show a greater number of fast colonic contractions and 
propagate contractions with subsequent accelerated transit. Conversely, patients with 
constipation predominant IBS have a decreased number of fast colonic and propagated 
contractions, and fewer high amplitude propagated contractions with slowed whole gut transit 
(Garnett, 1999). In patients with abdominal pain, a group of brief propagated intestinal 
contractions were identified, which are significantly increased compared with healthy controls 
(Muller-Lissner et al., 1999; Mach, 2004). Several factors such as strong emotion or 
environmental stress can lead to increased motility in the small intestine and colon of healthy 
subjects. IBS, however, is characterized by having an even greater motility response to 
stressors (psychological or physiological) when compared to normal subjects (Locke et al., 
2000; Drossman et al., 2002). 
Visceral Hypersensitivity 
Visceral hypersensitivity, modulated by several external and internal factors, is considered the 
most important factor in the pathophysiology of IBS and it helps to explain the association of 
pain with GI motility disorders, which leads to alterations in defecation patterns (diarrhea or 
constipation) (Katsanos et al., 2012). In laboratory practice, GI hypersensitivity is typically 
measured in response to the distension of a particular area of the GI tract. In the case of 
clinical studies, the subject has a balloon catheter inserted into the colorectal region and 
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graded isobaric or isovolumetric distensions are performed with the individual reporting their 
perception of the stimulus. It has been shown that many patients with IBS report lowered 
thresholds for all stimuli compared to healthy volunteers, and visceral hypersensitivity may be 
generally amplified in a subset of patients with IBS (Mertz et al., 1995; Lowen et al., 2015; 
Moloney et al., 2016). Repetitive balloon inflations in the colon lead to a progressive increase 
in pain intensity that occurs longer and to a greater degree in patients with IBS than in controls 
(Munakata et al., 1997; Drossman, 2006). In the gut, extrinsic nociceptors can respond to 
different kind of stimuli, depending on receptor expression, including stretch, pH, bacterial 
products, substances released from immune cells, and neurotransmitters released from the 
ENS or enterochromaffin cells (Sengupta, 2009). Hypersensitivity and sensitization may occur 
through altered receptor sensitivity at the gut mucosa, at the submucous and myenteric plexa, 
which may be enabled by mucosal inflammation, degranulation of mast cells close to enteric 
nerves, or increased serotonin activity, possibly enhanced by alteration of the bacterial 
environment or infection (Spiller, 2003; Barbara et al., 2004; Dunlop et al., 2005). 
The nociceptors have nerve endings throughout the layers of the GI tract (mucosal, 
submucosal, muscular layers), and their cell bodies are located in the dorsal root ganglion 
(DRG) of spinal cord (Figure 1.7). Then, the nociceptive signal is transmitted to the brain 
throughout the controlateral side of the spinal cord, and reaches cortical areas for localization 
and limbic areas for the emotional component of the pain response (Figure 1.7). In IBS an 
increased excitability with consequent central sensitization has been hypothesized (Moloney 
et al., 2016). A chronic or repetitive visceral stimulation may result in the growth of the dorsal 
horn of spinal cord, amplifying the throughput to the CNS (Moloney et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Central and peripheral pain sensitization. Increased pain perception can occur due to a 
combination of both central and peripheral sensitization (modified from Moloney et al., 2016). 
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Gut microbiota and inflammation in IBS 
The composition of the human gut microbiota as well as gut host immune homoeostasis may 
be crucial in the healthy status (Hébuterne, 2003; Guigoz et al., 2008). In physiological 
conditions, the gut microbiota has a balanced composition that ensures the host health, and 
disruption of this equilibrium (dysbiosis) confers disease susceptibility (Gibson et al., 2014). 
Moreover, several animal models (Bercík et al., 2004; Akiho et al., 2005; Verdù et al., 2006; 
Kanazawa et al., 2014) as well as clinical observations (Rao et al., 1987) have demonstrated 
that altered immune function and inflammation in the GI tract (as well as GI infections and 
dysbiosis) affect motility and sensitivity of the gut, two of the key pathophysiological factors in 
IBS (Akiho et al., 2005; Verma-Ghandu et al., 2007). 
Epidemiological and clinical studies revealed that a group of patients with IBS develops their 
chronic GI symptoms with the onset of gastroenteritis (postinfectious IBS) (Spiller and Garsed, 
2009). In fact, meta-analyses demonstrated a six fold to sevenfold increased risk of developing 
IBS after a gastroenteritis episode, which makes GI infections the best-characterized and 
probably strongest known risk factor for the development of this disease (Halvorson et al., 
2006; Thabane et al., 2007). Infective gastroenteritis produces a profound depletion of the 
commensal microbiota (Lupp et al., 2007) whose production of metabolites such as SCFAs 
together with the exposure to antibiotics normally determine the inhibition pathogen 
colonization (Barthel et al., 2003). Abnormalities in gut microbiota following enteric infections, 
associated with an increase in the permeability of epithelial gut barrier, might activate 
intestinal mast cells and monocytes triggering thus an immune response (Ohman and Simren, 
2010). Mast cells are important elements in the pathogenesis of inflammatory and non-
inflammatory bowel disorders, as they can cause stimulation of nerve endings, modulate 
inflammation and affect intestinal motility (Farhadi et al., 2007). Increased numbers of mast 
cells in close proximity to nerves in the colonic mucosa is one of the most frequently reported 
features of immune activity in IBS (Öhman et al., 2015). On the other hand, degranulation of 
mast cells after enteric infection or allergy might be the prime event that leads to the cascade 
of gut hypersensitivity through various mediators (Gui, 1998). Moreover, there is a recent 
demonstration that IBS patients have altered colonic mucosal expression of receptors 
recognizing specific microbiota-related substances (such as Toll-like receptor, TLRs). Increased 
mRNA levels of TLR2, TLR4 and TLR5 associated to mRNA levels of TLR7 and TLR8 have been 
found, in the colonic mucosa of patients with IBS, and these findings have also been confirmed 
at the protein level by immunohistochemical studies (Brint et al., 2011; Belmonte et al., 2012). 
Increased expression of TLR2 in blood monocytes from patients with IBS has also been 
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reported (Ohman et al., 2015). The expression of TLRs is upregulated by exposure to molecular 
structures of bacteria and viruses, which derived from altered microbiota. The crosstalk 
between luminal microbiota and the intestinal immune system influences GI motility (as 
demonstrated in animal models). For instance, the absence of TLR4, a receptor commonly 
expressed on innate immune cells that recognizes lipopolysaccharide from Gram-negative 
bacteria, results in substantial reduction in GI motility in mouse models (Anitha et al., 2012). 
Moreover, intestinal macrophages regulate peristaltic activity of the colon by changing the 
pattern of smooth muscle cell contractions in the presence of luminal microbiota (Muller et al., 
2014; Robinette and Colonna, 2014). 
Another reported immune-related feature in patients with IBS is increased levels of circulating 
proinflammatory cytokines such as IL‑6, IL‑8, TNF and IL‑1β (Scully et al., 2010; Chang et al., 
2012), which may have an effect on epithelial barrier function. Thus, even a quite small 
increase in levels of proinflammatory cytokines at the epithelial barrier can lead to increased 
intestinal permeability, and thereby altered homeostasis at the mucosal border (Ohman et al., 
2015). 
Psychosocial Factors 
It is well known that IBS reduces quality of life, which may have psychological consequences 
(Mach, 2004). In healthy subjects psychological stress affects GI function and produces 
symptoms that are emphasized in patients with IBS (Kroenke and Mangelsdorff, 1989). 
Psychiatric problems such as somatization, anxiety, hypochondriasis, depression, and phobia 
are common in about 50% of patients with IBS at the time of diagnosis (Quigley, 2003). These 
factors in patients with IBS influence not only the illness experience, but also the treatment 
outcome. Psychosocial and sociocultural factors include: a history of emotional, sexual, or 
physical abuse, stressful life events, chronic social stress, or anxiety disorder, and maladaptive 
coping style and often some of these may occur early in life (Drossman et al., 2002). These 
factors can be reduced or “buffered” by adaptive coping skills and social support, and the 
psychosocial response of family, society, and culture can also have a palliative effect on the 
illness experience. 
Gut-brain axis 
From the evidence discussed above, it is clear that IBS is a multifaceted disorder where both 
central and peripheral factors are involved; thus, it is most commonly described as a 
biopsychosocial disorder of the gut-brain axis. The gut–brain axis encompasses a number of 
fundamental elements, including the CNS, the autonomic nervous system (ANS) (sympathetic 
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and parasympathetic), the ENS, the neuroendocrine hypothalamic–pituitary–adrenal axis 
(HPA) axis, and neuroimmune systems, and more recently has expanded to include the gut 
microbiota, which fulfill key roles in bidirectional communication (Bercik et al., 2011; Cryan 
and Dinan, 2012; Burokas et al., 2015). The microbiota–gut–brain axis is pivotal in maintaining 
homeostasis and is involved in the control of diverse physiological functions including motor, 
sensory, autonomic, and secretory functions of the GI tract to regulate an array of processes 
from energy metabolism to mood regulation (Burokas et al., 2015; Dinan et al., 2015). 
Communication between CNS and ENS implies a bidirectional connection system: the brain 
influences the function of the ENS, and the gut influences the brain via vagal and sympathetic 
afferents. The ENS independently controls gut function, the migrating motor complex, and 
peristalsis, but it is constantly monitored and modified by CNS via both vagal and sympathetic 
extrinsic nerves. Thus, the IBS symptoms may be caused by dysfunctions either primarily in the 
CNS, or in the gut, or by a combination of both (Moloney et al., 2016). 
Genetic Predispositions 
Epidemiological studies of familial aggregation suggest a genetic contribution to IBS (Camilleri 
and Katzka, 2012). Genetic factors may predispose some individuals to develop typical 
symptoms observed in IBS whereas in others, environmental factors contribute to the 
phenotypic expression of these conditions (Drossman, 2006).  
Serotonin is predominantly known for its role in the brain, where it functions as a 
neurotransmitter; however, approximately 95% of serotonin in the body is contained within 
the gut, specifically, in the enterochromaffin cells of the mucosa and in the nerve terminals of 
the ENS neurons. In peripheral tissues, serotonin is involved in regulation of GI motility, 
secretion, and sensory perception (Costedio et al., 2007; Mc Lean et al., 2007). Its central 
functions include the regulation of mood, cognitive function, and central processing of sensory 
signals involved in pain perception (Wrase et al., 2006; Yano et al., 2015). Serotonin signaling 
may be a key linker in communication along gut-brain axis (O'Mahony et al., 2015), thus 
dysfunction of these pathways may underlie the pathological symptoms present in both GI and 
mood disorders, and may also explain the high comorbidity of these disorders (Camilleri and 
Katzka, 2012; Moloney et al., 2016). For this reason, polymorphisms related to 
neurotransmitter levels, such as serotonin reuptake transporter, and signaling, such as 
serotonin receptors, are being explored for understanding IBS pathophisiology. 
Several studies also have emphasized the role of CNS-related genetic abnormalities in IBS. The 
ANS is involved in the regulation of GI motility and, consequently, alteration of this part of the 
nervous system is linked to IBS (Drossman, 2006; Katsanos et al., 2012). In general, adrenergic 
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transmission, as part of the autonomic nervous system, directly modulates gut function and 
sensation (Bharucha et al., 1997; Viramontes et al., 2001). The α2-adrenergic receptor has also 
been proposed as a mechanism whose genetic variation may modify motor and sensory 
functions in IBS (Kim et al., 2004). A relationship between IBS and commonly observed co-
morbidities such as post-traumatic stress disorder, depression, and anxiety disorders is 
represented by the Val158Met polymorphism of catechol-O-methyltransferase enzyme. This 
genetic variation influences the human experience of pain and may underlie inter-individual 
differences in the adaptation and responses to pain and other stressful stimuli (Zubieta et al., 
2003). 
1.5 Role of cathecol-O-metyltrasferase in the pathophysiology of IBS 
Catechol-O-methyltransferase (COMT) is one of the enzymes that catalyzes the methylation of 
catechol structures, including dopamine (DA), norepinephrine (NE), epinephrine, caffeine, and 
catechol estrogens (Axelrod and Tomchick, 1958). Expression of the COMT enzyme is under 
the control of two separate promoters. One gives rise to a short mRNA (1.3 kb in human and 
1.6 kb in rat), which produces the soluble isoform (S-COMT) in the cytoplasm. The other 
produces the long mRNA (1.5 kb in human and 1.9 kb in rat), yielding both soluble and 
membrane-bound isoforms (MB-COMT) (Mannisto and Kaakkola, 1999). Humans Comt gene is 
located on chromosome 22q11.2 and it consists of 6 exons, the first two non-coding, while in 
the third are located the two promoters that control COMT isoforms expression (Salminen et 
al., 1990; Lundstrom et al., 1991). In peripheral tissues, the S-COMT is the most prevalent 
isoform of COMT enzyme and MB-COMT activity represents generally less than 5% of the total 
COMT activity (Guldberg and Marsden, 1975; Jeffery and Roth, 1984; Grossman et al., 1985). 
However, in some human tissues, like the brain, the amount of MB-COMT activity has been 
reported to be higher (Rivett et al., 1983; Tenhunen et al., 1994). The two isoforms of COMT 
are proposed to have at least partially distinct roles. It seems that at the concentrations of 
catecholamines (DA and NE) naturally present, MB-COMT may be more important in their 
metabolism (Roth, 1992). Therefore MB-COMT is the predominant enzyme at DA 
concentration of <10 µM and at NE concentration of <300 µM. In addition, MB-COMT also has 
a higher affinity for catechol substrates and a lower Km value for DA than S-COMT (Myöhänen 
et al., 2010). On the other hand, S-COMT is a high capacity enzyme isoform indicated by higher 
Vmax values than those of MB-COMT (Lotta et al., 1995).  
In both mouse and human specimens, COMT expression has been detected in the liver, 
kidneys and GI tract (Nissinen et al., 1988). COMT has a protective role in the elimination of 
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biologically active or toxic catechols, particularly xenobiotics, acting as an enzymatic 
detoxifying barrier between the blood and other tissues (Mannisto and Kaakkola, 1999). COMT 
also inactivates L-DOPA, a catechol-containing drug used as a dopamine precursor in the 
treatment of Parkinson's disease (Ball et al., 1972; Guldberg and Marsden, 1975). Due to its 
harmful effect on the medication of Parkinson's disease, a great deal of interest has been 
directed towards the development of specific COMT inhibitors (Guldberg and Marsden, 1975; 
Mannisto and Kaakkola, 1999). Next to the earlier primary role of COMT in peripheral 
detoxification, it has emerged in the last years the importance of this enzyme in the central 
neurotransmission. 
COMT protein is widely distributed in mammalian brain (Lundstrom et al., 1995; Mannisto and 
Kaakkola, 1999) and its enzyme activity regulates DA levels (Yavich et al., 2007). In the 
striatum, the synaptic action of DA is thought to be largely terminated by neuronal uptake by 
the abundant presence of DA transporters (Giros et al., 1996). However, in the prefrontal 
cortex DA transporters are expressed at low levels within synapses, thus alternative 
mechanisms, such as degradation by COMT, might be a key process in the regulation of DA 
availability in this brain area (Garris et al., 1993; Lewis et al., 2001; Wayment et al., 2001). In 
humans as well as in monkeys, rats, and mice, cortical DA signaling affects cognitive 
performance through a U-shaped relationship, showing that too little or too much DA having 
deleterious effects (Mattay et al., 2003; Vijayraghavan et al., 2007). For this reason, COMT has 
an important role in regulating higher cognitive processes in mammals via the modulation of 
central neurotransmission, especially DA (Chen et al., 2004; Papaleo et al., 2008). In CNS, 
genetic variations in human COMT have been associated with physiological functions (Egan et 
al., 2001; Winterer et al., 2006) and behavioral phenotypes related to prefrontal cortex and 
hippocampal information processing, including cognition (Blasi et al., 2005; Bertolino et al., 
2006), anxiety (Drabant et al., 2006), obsessive-compulsive disorder (OCD) (Pooley et al., 
2007), and pain sensitivity (Nackley et al., 2006). Thus, functional COMT genetic variations 
modulate multiple spheres of mammalian behavior, with remarkable analogy between human 
and mouse (Papaleo et al., 2008; Mier et al., 2010; Scheggia et al., 2012; Papaleo et al., 2012). 
A common polymorphism of this gene in human populations is Val158Met (rs4680). This 
polymorphism is a functional genetic variant determined by a valine to methionine 
substitution at codon 108 (S-COMT)/158 (MB-COMT) of the COMT gene and dramatically 
impacts COMT enzymatic activity (Lotta et al., 1995; Palmatier et al., 1999). At normal body 
temperature, the COMT-Val form leads to higher COMT protein levels and enzymatic activity 
compared with COMT-Met (Chen et al., 2004). Due to the potential importance of COMT in 
prefrontal DA neurotransmission, this common functional polymorphism has been studied in 
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association with neuropsychiatric disorders that may involve altered DA levels (Papolos et al., 
1998; Eisenberg et al., 1999; Jones et al., 2001). Because there is only one COMT gene without 
any known tissue-specific splice variants (Tenhunen et al., 1994; Lundstrom et al., 1995), it is 
likely that the codon 108/158 polymorphism, causing changes in protein thermostability, also 
leads to functional alterations of COMT in all tissues (Lachman et al., 1996, Mannisto and 
Kaakkola, 1999).  
Recently, it has been hypothesized an association between gut functional disorders such as IBS 
and COMT Val158Met polymorphism (Camilleri and Katzka, 2012; Karling et al., 2011). While 
IBS is multifactorial, with no single etiology to completely explain the disorder, many patients 
also experience comorbid behavioral disorders, such as anxiety or depression, thus IBS can be 
described as a disorder of the gut–brain axis (Moloney et al., 2016). In the brain, COMT-met 
variant, associated with low COMT activity, determines higher levels of DA and chronic 
activation of dopaminergic neurons which results in lower neuronal content of enkephalin and 
a decreased activity level of the endogenous pain inhibitory system (Zubieta et al., 2003). 
Experimental studies in humans (hypertonic saline infusion into the masseter muscle) showed 
that individuals with the met/met genotype exhibited diminished regional µ-opioid receptors 
activity, higher sensory and affective ratings of pain in response to painful stimuli compared to 
the val/val individuals (Zubieta et al., 2003; Karling et al., 2011). Low COMT activity has also 
been associated to chronic pain conditions such as facial pain (Marbach and Levitt, 1976; 
Diatchenko et al., 2005), fibromyalgia (Gürsoy et al., 2003) and with non-migraine headache 
(Hagen et al., 2006), whereas the val/val genotype has been associated to anxiety/ depression 
(Domschke et al., 2007).  
On the background that both chronic pain syndromes (Whitehead et al., 2002) and 
anxiety/depression (Mayer et al., 2001; Garakani et al., 2003) are associated to low and high 
COMT activity, respectively, and both are related with IBS and IBS-like symptoms, these two 
genotypes may be a risk factor for the onset of IBS possibly via separate mechanistic routes, 
whereas the val/met (intermediate COMT activity) genotype can be considered the low risk, 
protective genotype (Karling et al., 2011).  
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2. AIM 
The importance of mutual interactions among different cell populations, that constitute the 
enteric microenvironment (i.e. neurons, glial cells, smooth muscle cells, interstitial cells of 
Cajal, macrophages and microbes), in remodelling the neuronal network in response to a 
neuromuscular damage, is widely acknowledged, however, the molecular mechanisms are still 
largely unexplored. Gut microbiota seems to be directly involved in modulating the 
development and function of enteric nervous system (ENS), supporting the concept that 
changes in commensal microbiome composition, induced by infections or antibiotics, can 
perturb ENS integrity and activity. Several studies focused on the microbiome of animal 
models have underlined the “bottom-up” impact of microbes and their importance in 
governing ENS and CNS homeostasis. Neuronal circuitries in the ENS communicate with the 
CNS and vice versa via vagal and sympathetic extrinsic pathways, the so-called gut-brain axis, 
that in recent years has emerged as an important microbiota-to-brain communication 
pathway. The relationship between indigenous gut microbes and their host can shift from 
commensalism towards pathogenicity in diseases, such as inflammatory bowel disease (IBD), 
ischemia/reperfusion (I/R) injury and psychiatric disorders.  
The mammalian gut must be sufficiently permeable to support absorption of nutrients, 
however, it must also avoid potentially damaging immune responses. Both nonpathogenic 
bacteria and activation of innate defenses help prevent pathogenic bacteria from crossing the 
mucosal barrier. When this homeostasis is perturbed, the immune system may react to both 
exogenous and endogenous ‘danger signals’ via activation of Toll-like receptors (TLRs). 
Polymorphisms in genes encoding TLRs, including TLR2 or TLR4, have been associated with 
different phenotypes of disease extent and severity in patients with GI disorders.  
In this study we aimed to determine the impact of i) commensal microbiota depletion, ii) 
altered TLR2 and/or TLR4-mediated innate immunity response, iii) genetic-driven defective 
COMT activity, in the structural and functional integrity of murine ENS and consequently in 
gastrointestinal homeostasis. 
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3. MATERIALS AND METHODS 
Mice 
The first group of transgenic animals consists of male TLR2-/- (B6.129-Tlr2tm1Kir/J; postnatal 
days 21, P21) and age-matched wild-type (WT) C57BL/6J mice (Charles River Laboratories, 
Italy), that were used in order to examine the role of TLR2 signaling in maintaining ENS 
homeostasis and gut function. A second group consists of female heterozygous for COMT gene 
(C57BL/6J COMT+/−, Charles River Laboratories, Italy) and wild-type (COMT+/+, WT) mice (12±2 
weeks) that were used to evaluate the influence of altered catecholaminergic transmission, 
due to COMT genetic reduction, in modulating gastrointestinal motility. These animals were 
provided by the research group of Dr. Francesco Papaleo from Italian Institute of Technology, 
Genova, Italy. Their genotypes were confirmed by PCR analysis of mouse tail DNA. All groups of 
mice were housed in the pathogen-free animal facility of the Department of Pharmaceutical 
and Pharmacological Sciences of the University of Padova under controlled environmental 
conditions (temperature 22° ± 2°C; relative humidity 60–70%) with free access to a standard 
diet and water, and maintained at a regular 12/12-h light/dark cycle. To normalize gut 
microbiota, mice colonies from both groups were housed in the same room and generally in 
the same cages and maintained by the same personnel. All experimental protocols were 
approved by the Animal Care and Use Ethics Committee of the University of Padova and by the 
Italian Ministry of Health and were in compliance with national and European guidelines for 
the handling and use of experimental animals.  
Mice treatments 
For depletion of intestinal microbiota male mice C57BL/6J (3±1 weeks old; Charles River 
Laboratories, Italy) were subjected to a previously published protocol that produces a germ 
free-like phenotype (Reikvam et al., 2011; Brun et al., 2013) which consisted in a cocktail of 
broad spectrum antibiotics (50 mg/kg vancomycin, 100 mg/kg neomycin, 100 mg/kg 
metronidazol and 100 mg/kg ampicillin, ABX group) (Figure 3.1), administered to mice by oral 
gavage (100 µl volume/mouse) every 12 hours for 14 days, using a stainless steel feeding tube 
without prior sedation of the animal. Control mice (CNTR group) were treated with vehicle (tap 
water). Microbiota-depletion efficacy was confirmed by performing 16S ribosomal RNA gene 
quantification in mouse feces, as described previously (Brun et al., 2013).  
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Figure 3.1. Antibiotic-induced changes in the microbiota composition and relative effect on immunity 
(modified from Ubeda and Pamer, 2012). 
In order to verify the relationship between an adequate GDNF availability and a correct 
development of ENS, TLR2-/- mice were treated in vivo with rGDNF (Brun et al., 2013). 
Recombinant histidine-tagged (six His–tag) GDNF (rGDNF) was expressed in Escherichia coli 
and purified as described previously (Creedon et al., 1997).After elimination of endotoxin by 
gel chromatography (Pierce, Rockford, IL), endotoxin contamination was lower than 0.1 
pg/dose (Lymulus Amoebocyte Assay; BioWhittaker, Walkersville, MD). TLR2-/-and WT mice 
P14 were injected with either rGDNF (2 μg /g in 0.9% saline, subcutaneously) or endotoxin-free 
saline once a day for 7 days and analyzed at P21 (Wang et al., 2010).  
To evaluate the influence of the activation of TLR2-mediated signaling in microbiota-depleted 
micePam3CysSerLys4 (Pam3-CSK4; TLR1/TLR2 heterodimer agonist; Invivogen, 2 mg/kg in 0.9 
% saline, intraperitoneally) was administered daily to ABX mice during the second week of 
antibiotic treatment (from P28 to P35) for 7 days.  
To investigate the effect of inhibition of both TLR2 and 4-mediated signaling on intestinal 
function, male WT mice P14 were treated with 1-palmitoyl-2-arachidonyl-snglycero-3-
phosphorylcholine (OXPAPC, Invivogen; 1.5 µg/g in 0.9% saline) (Figure 3.2), a mixture of 
oxidized phospholipids, which was administered intraperitoneally once a day for 7 days. No 
signs of illness were evident during different treatments. 
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Figure 3.2. Mechanism of blocking the signaling of TLR2 and TLR4 by OXPAPC and composition of 
mixture of oxidized phospholipids (OXPAPC; Erridge et al., 2008). 
Histopathology 
Ileal specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. From 
each paraffin block at least three sections 4-5 μm-thick were sliced and stained with 
hematoxylin-eosin (H&E). Intestinal slides (n=6) were assessed in a blinded manner. A 
minimum of 10 independent fields per animal was examined at low (x10) and high (x40) 
magnification.  
Immunohistochemistry 
Immunohistochemical analysis was performed with the DAKO Autostainer plus (DAKO 
Cytomation). Paraffin-embedded ileal sections were deparaffinized in xylene, rehydrated, and 
pretreated in EnVisionTM FLEX Peroxidase-Blocking Reagent (DAKO) to block endogenous 
peroxidase activity. Sections were then rinsed in phosphate buffered saline (PBS) and 
incubated with anti-GDNF diluted in EnVisionTM FLEX Antibody Diluent for 30 min at room 
temperature. Primary antibody binding was revealed by incubation with EnVisionTM FLEX + 
rabbit linker (DAKO) for 15 min at room temperature and EnVisionTM FLEX/horseradish 
peroxidase for 20 min at room temperature. Developing solution was composed of 
EnVisionTM FLEX substrate buffer and EnVisionTM FLEX DAB + chromogen for 10 min at room 
temperature. Lastly, sections were counterstained with haematoxylin and then dehydrated, 
cleared with xylene and mounted. Negative controls were performed by omission of primary 
antibody and by pre-adsorption of antibody with recombinant GDNF for 1 hour at room 
temperature. Mouse brain sections were used as positive controls. Examination of the sections 
was performed under a Leica DM4500B microscope (Leica Microsystems) connected with a 
Leica DFC320 high-resolution digital camera (Leica Microsystems) and a computer equipped 
46 
 
with Leica Application Suite Version 2.8.1 software for image acquisition (Leica Microsystems; 
Brun et al., 2013). 
Immunofluorescence 
Immunofluorescence analysis was performed on ileal tissues embedded in optimal cutting 
temperature mounting medium (Tissue Tek Sakura) and frozen in dry ice (-80°C). Tissues were 
sectioned (7 µm-thick) with a cryostat-microtome (Leica CM 1850 UV), and then slices were 
fixed in 4% paraformaldehyde for 20 minutes at room temperature (RT). The aldehydes form 
covalent bonds between adjacent amine-containing groups through a Schiff acid-base 
reaction, which leads to formation of methylene bridges and other types of links (Collins and 
Goldsmith, 1981; Fox et al., 1985). However, unreacted aldehyde groups can emit fluorescence 
efficiently at the same wavelengths similar to the fluorescent probes employed for 
immunofluorescence assays. Fixative-induced autofluorescence was circumvented by treating 
fixed section for 20 minutes with 50 mM NH4Cl, an exogenous amine-containing reagent that is 
able to quench fluorescence emission of unreacted aldehydes (Diez-Fraile et al., 2012). After 
repeated washings with Tris-buffered saline (TBS), samples were permeabilized with 0.3% 
Triton X-100. Non-specific binding sites were blocked incubating slides for 1 h with 2% bovine 
serum albumin (BSA) added together with the Triton X-100-containing solution. After TBS 
wash, ileal samples were incubate with primary antibodies listed in Table 3.1, diluted in TBS-
0.5% BSA for 1 hour at RT. Immunocomplexes were visualized by incubating samples with the 
appropriate secondary antibodies listed in Table 3.2, for 1 h at RT. Nuclei were stained with 
TOTO-3 iodide (1:500; Life Technologies, Milan, Italy) added together with the secondary 
antibodies. Sections were mounted on glass slides using Mounting Medium (Sigma-Aldrich, 
Italy). Negative controls were obtained by incubating sections with isotype-matched control 
antibodies at the same concentration as primary antibody (data not shown). Images of a 
number of ileal areas, corresponding to the longitudinal smooth muscle layer (LM), circular 
smooth muscle layer (CM), myenteric ganglia (MG), submucosal ganglia (SMG) and mucosal 
layer (ML) were acquired with a Nikon System Spinning Disk confocal microscope. All 
microscope settings were set to collect images below saturation and were kept constant for all 
images.  
47 
 
Whole mount staining  
Preparation of ileal whole mount samples 
Animals were killed by cervical dislocation and the ileum was quickly isolated and washed with 
Krebs solution, to remove any contents. Then, distal ileal 10 cm-segments were filled with 
fixative solution consisting of 4% paraformaldehyde in PBS. Two hours were allowed for the 
fixation which occurred at 22°C and later tissues were cleared of fixative with2 x 30 minutes 
washes in PBS. Tissues were stored at 4°C in PBS containing 5% sodium merthiolate 
(Thimerosal, Sigma-Aldrich, Italy). Segments were cut in 0.5 cm-pieces and an incision was 
made along the midline of the gut. Using a dissecting microscope, tissues were pinned as a flat 
sheet onto wax support with the mucosa face-down and were separated into two layers: the 
outer musculature with adhering serosa and the submucosa/mucosa. The circular muscle was 
removed to yield whole-mounts of longitudinal muscle with the myenteric plexus attached 
(LMMP; Ruan and Burnstock, 2005). The LMMP whole-mount preparations were processed for 
acetylcholinesterase and NADPH-diaphorase biochemical staining or for immunohistochemical 
analysis. 
Acetylcholinesterase and NADPH-diaphorase biochemical staining in ileal 
whole mount preparations 
For acetylcholinesterase staining, the fixed tissue was washed in PBS and incubated in fresh 
copper buffer solution (100 ml dH2O, 7.2 mg ethopropazine, 115.6 mg acetylthiocholine iodide, 
75.0 mg glycine, 50.0 mg copper sulfate pentahydrate, 885.0 mg sodium acetate trihydrate; pH 
to 5.6 with glacial acetic acid) for 2 hours. This was followed by a wash in dH2O, 1 minute in 
1.25% sodium sulfide nonahydrate solution, a second wash in dH2O, then mounting of the 
tissue on a glass slide. For NADPH diaphorase staining, the fixed tissue was washed in PBS and 
incubated in diaphorase solution (β-NADPH, 1 mg/ml; nitroblue tetrazolium (NBT), 0.1 mg/ml; 
and 0.3% Triton-X 100 in PBS) for 1 hour at 37°C. This was followed by washing in PBS and 
mounting of the tissue on a glass slide (Anitha et al., 2006). Samples from biochemical staining 
were observed using a Leica DM4500B microscope. Myenteric fiber count was performed on 
both acetylcholinesterase and NADPH diaphorase–stained intestines by counting fibers 
crossing a 0.1 mm2 grid with 10 horizontal and 10 vertical lines. Twenty randomly selected 
fields per mouse were evaluated from 5 animals of each group. Total number of fibers was 
expressed as positive fibers per grid. 
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Immunohistochemistry on whole mount preparations 
LMMP preparations were also used for immunohistochemistry. Ileal tissues, gently stretched 
and pinned down on a wax support as described before, were washed with PBS 0.3% Triton X-
100 (PBS-T) for 45 minutes with slow shaking. Preparations were incubated in 2% BSA in PBS-T 
for 1 h at RT prior to the primary antibody incubation. Whole mount preparations were then 
incubated with the antibodies listed in Table 3.1 diluted in PBS-T/BSA 2%, overnight at RT. The 
following day, preparations were washed for 45 minutes in PBS-T prior to the appropriate 
secondary antibodies incubation, listed in Table 3.2, for 2 h at RT. TOTO-3 iodide (1:500; Life 
Technologies, Milan, Italy), a fluorescent probe for staining cell nuclei, was added to secondary 
antibodies solution. Three subsequent 15 minutes washes in PBS-T were given and LMMP 
preparations were then mounted on glass slides using a Mounting Medium (Sigma-Aldrich, 
Italy) and imaged with a Nikon System Spinning Disk confocal microscope. 
Imaging and myenteric ganglia analysis 
Preparations were imaged using a Nikon System Spinning Disk confocal microscope equipped 
with Nikon Plan APO 60.0X/1.40 and Plan APO 40X/0.95 oil immersion objectives. 
Fluorophores were visualized using a 488 nm excitation filter and 515/535 nm emission filter 
for Alexa Fluor 488, 543 nm excitation filter and 565/590 nm emission filter for Alexa Fluor 
555, and 637 nm excitation and 650/660 nm emission filter for TOTO-3 iodide. Z-series and 
single 1024 x 1024 pixel images were captured. Images were composed of 10 to 15 plane 
forming Z-stack of 4-6 animals per group. Z-stacks of 8-µm or 10-µm depth were obtained for 
LMMP whole-mount preparations or for ileal frozen sections and processed as maximum 
intensity projections. All microscope settings were set to collect images below saturation and 
were kept constant for all images. In LMMP whole mount preparations we analyzed images of 
myenetric ganglia for HuC/D+, neuronal nitric oxide synthase (nNOS)+ neurons and S100β+ glial 
cell bodies for counts and calculation of myenteric ganglia area. Number of cells was recorded 
within a minimum of 5 randomly selected fields covering 1.254 mm2 from at least three LMMP 
preparations per mouse for a total of 6 animals of each experimental group. Ganglionic area 
was estimated using NIH Image J software. HuC/D, S100β, nNOS and GFAP immunoreactivities 
were determined in ileal frozen sections by measuring the area (number of pixels) and 
fluorescent intensity (average intensity of pixels) of staining from 24 images captured 
randomly in the ileal neuromuscular compartment from each CNTR and ABX tissue samples 
(n=4). Simultaneously, the mean intensities of HuC/D, S100β, nNOS and GFAP signals were 
normalized to mean TOTO-3 intensities for each neuron. Fluorescence values were expressed 
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as mean values in arbitrary fluorescence units (A.U.). Image analysis and quantification of the 
fluorescence intensity were performed using ImageJ software (version 1.48a). 
 
 
 
 
 
 
Table 3.1. Characteristics of the primary antibodies used in immunofluorescence analysis. 
Table 3.2. Characteristics of the secondary antibodies used in immunofluorescence analysis. 
In vitro contractility studies 
Intestinal contractility was examined in vitro by measuring tension changes on ileal samples 
with the isolated organ bath technique. Experiments were performed on full-thickness distal 
ileum segments isolated from TLR2-/-, ABX, COMT+/- and respective control mice (CNTR). After 
the mice were sacrificed, the small intestine was placed into oxygenated (95% O2 and 5% CO2) 
Krebs solution with the following composition (mM): NaCl 118, KCl 4.7, CaCl2∙2H2O 2.5, 
MgSO4∙7H2O 1.2, KH2PO4 1.2, NaHCO3 25, glucose 11; pH=7.4) at 37° C. The last section of the 
intestine was removed and 1cm ileal segments were taken for use in this experiment. Contents 
ANTIGEN (HOST) CLONE SOURCE DILUTION 
nNOS (rabbit) polyclonal Life Technologies 1:100 
βIII-tubulin (rabbit) polyclonal COVANCE 1:400 
HuC/D (mouse) 
Biotin conjugated 
16A11 
Life Technologies 1:50 
GFAP (rabbit) polyclonal Merk Millipore 1:200 
S100β (rabbit) EP1576Y Merk Millipore 1:100 
TLR2 (mouse) T2.5 eBioscience 1:100 
Peripherin (rabbit) polyclonal Merk Millipore 1:100 
GDNF (rabbit) D20 
Santa Cruz 
Biotechnology 
1:100 
ANTIGEN (HOST) CLONE SOURCE DILUTION 
goat anti-rabbit IgG 
Rhodamine-
conjugate 
Chemicon 1:1000 
goat anti-mouse IgG 
Alexa Fuor 
488-conjugate 
Life Technologies 1:1000 
goat anti-rabbit IgG 
Alexa Fuor 
555-conjugate 
Life Technologies 1:1000 
goat anti-rabbit IgG 
Alexa Fuor 
488-conjugate 
Life Technologies 1:1000 
Streptavidin 
Alexa Fuor 
555-conjugate 
Life Technologies 1:1000 
Streptavidin 
Alexa Fuor 
488-conjugate 
Life Technologies 1:1000 
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were washed with Krebs solution using a syringe. At each end of the ileal segment, thread was 
used to create a loop; one side was placed through the hook of an organ bath and the other 
side was connected to an isometric transducer. These segments were vertically mounted in 10 
mL volume organ baths filled with 10 mL Krebs solution; tension was set to 1g. Isometric 
transducers (WPI, USA) connected to a quad bridge amplifier and PowerLab 4/30 data 
acquisition system using LabChart6 software (ADInstruments, UK) were used to record the 
changes in muscle tension. Initially each segment was allowed to equilibrate for 30 minutes. 
Thereafter the segment was activated with 1 µM carbachol stimulation. At first, the ileal 
segments were exposed to carbachol stimulations of the following concentrations (0.01-100 
µM) to obtain a concentration-response curve. To evaluate the smooth muscle response, we 
subjected the segments to 60 mM KCl. Electrical field stimulation (EFS) was used after to evoke 
neuronal-mediated contractions (at 2-50 Hz; 1-ms pulse duration; 10-s pulse-trains, 40 V) by 
the ileal segments. For this, segments were placed between parallel electrode pairs that were 
connected to a Grass S88 stimulator (Grass Instrument Co. Quincy, MA.). To evaluate the 
response in relaxation in non-adrenergic non-cholinergic (NANC) conditions, the same EFS 
parameters were used for inhibition following an incubation period of 20 minutes with 1 μM 
atropine and 1 μM guanethidine. To block nitrergic-mediated neurotransmission, 100 µM Nω-
nitro-l-arginine methyl ester (L-NAME), an inhibitor of NOS, was incubated within the same 
NANC conditions for an additional 20 minutes and EFS occurred after this period. 
Concentration-response curves were subjected to a nonlinear regression analysis (fitted to a 
sigmoidal equation) to calculate maximal tension (Emax) values (Brun et al., 2013). The 
relaxation response was quantified by calculating the area under the curve defined as the 
integrated area under the waves (AUC). 
Gastrointestinal Transit Analysis  
The gastrointestinal (GI) transit was measured by evaluating the intestinal distribution of orally 
gavaged fluorescein isothiocyanate (FITC)-labeled dextran (70 kDa) from the stomach to the 
colon. With regard ABX treatment or COMT+/- transgenic model, treated and control mice were 
administered FITC-dextran dissolved in 0.9% saline (100 µl of 25mg/ml FITC-dextran solution 
for each mouse). Then mice were sacrificed after 30 minutes and the complete GI tract from 
stomach to distal colon was collected. The stomach and caecum were analyzed separately 
while the small intestine was divided into 10 segments of equal length and the colon was 
divided into 3 segments of equal length. However, for TLR2-/-and respective controls, mice 
were sacrificed 60 minutes after administration of FITC-dextran and the bowel was removed. 
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The stomach, caecum and colon were examined separately, whereas the small intestine was 
divided in 8 equal segments. Luminal contents from each part (both tissue and faecal content) 
were collected and clarified by centrifugation (12,000 rpm for 10 minutes at 4°C). Supernatant 
from each sample were placed into separate wells of a 96 well plate and assayed in duplicate 
along with a Krebs solution control and a FITC-dextran control (1:10 part dilution of FITC-
dextran and Krebs solution respectively). FITC-dextran fluorescence intensity was measured at 
492/521 nm using a fluorimeter (Victor, PerkinElmer). The data collected were expressed as 
percentage (%) of fluorescence for each segment and GI transit was calculated as the 
geometric center (GC) of distribution of the fluorescent marker using the following formula 
(Wehner et al., 2007): 
GC = ∑ (% of total fluorescence signal x segment * segment number)/100 
Pellet frequency and fecal water content 
Fecal pellet output and water content was assessed in mice following antibiotic treatment. 
Fecal water content provides an indication of constipation, diarrhea or malabsorption. ABX 
and CNTR mice were placed into individual clean cages and were examined throughout a 60-
minute-period. All animals were given standard chow diet and tap water ad libitum during the 
observation time. Fecal pellets were collected at 15 minute intervals into a 1.5-mL-
microcentrifuge tube weighed beforehand. The numbers of pellets collected were tabulated; 
tubes were weighed to acquire the wet weight of the pellets initially. Then the pellets were 
dried overnight at 65°C and reweighed to obtain the dry weight. The difference in wet and dry 
weight was expressed over the dry stool weight to calculate fecal water content (Li et al., 2006; 
Anitha et al., 2012). 
Bone marrow chimera mice 
Two bone marrow chimera groups were produced and experimental transfers were as follows: 
WT donors into WT recipients (WT→WT), WT donors into TLR2-/- recipients (WT→TLR2-/-), 
TLR2-/- donors into TLR2-/- recipients (TLR2-/-→TLR2-/-), and TLR2-/- donors into WT recipients 
(TLR2-/-→WT). All recipients and donors were male between 7 and 8 weeks of age. Bone 
marrow cells (BMCs) were obtained as previously described (Sanders et al., 2008; Brun et al., 
2013). Briefly, donor mice (C57BL/6J or TLR2-/-) were killed and BMCs from were flushed out 
from femurs and tibiae with Dulbecco's Modified Eagle's Medium (DMEM), by means of a 27 
gauge needle, filtered through BD Falcon cell strainers to mesh clumps, and wash twice with 
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DMEM. Finally, the isolated cells were sediment by centrifugation at 1500 rpm for 5 minutes at 
4°C, then pellet was resuspended in DMEM. The BMCs suspension was divided into 100-µl 
aliquots containing at least 1x107 cells, which were stored at 4°C until use. Recipient mice were 
exposed to a single dose of 10-Gy whole-body γ-radiation using a linear accelerator (γ-source), 
injected intravenously with 1×107BMCs from donors via the tail vein using a 27-gauge, and 
allowed to reconstitute for two months. All chimeras were kept on drinking water containing 
40 mg/L neomycin sulfate (Sigma Aldrich, Italy) for four to six weeks before returning to 
regular water. Four and six weeks after bone marrow reconstitution, peripheral blood 
chimerism in leukocytes expressing TLR2was assessed by fluorescence-activated cell sorter 
(FACS) analysis. Only recipients exhibiting peripheral blood chimerism greater than 85% were 
used for further analysis (Brun et al., 2013). 
RNA isolation and quantitative RT-PCR 
GluN1 expression in ABX or COMT experimental groups was assessed by RT-PCR in 
collaboration with the research group directed by Prof. Cristina Giaroni, University of Insubria, 
Varese. Briefly, total RNA was extracted from longitudinal muscle/myenteric plexus (LMMP) 
preparations with TRIzol (Invitrogen, Italy) and treated with DNase I (DNase Free, Ambion, 
Italy) to remove any traces of contaminating DNA. cDNA was obtained retrotranscribing 2 ug 
of total RNA using the High Capacity cDNA Synthesis Kit (Applied Biosystems, Life 
Technologies, Italy). Quantitative RT-PCR was performed on the Abi Prism 7000 real-time 
thermocyclator (Applied Biosystems, Italy) with Power Sybr Green Universal PCR Master Mix 
(Applied Biosystems, Italy) according to the manufacturer’s instructions. Primer sequence was: 
NR1, 5-CAGGAGCGGGTAAACAACAGCAAC-3; 5-GCAGCCCCACCAGCAGCCACAGT-3; β-actin 5-
ACCAGAGGCATACAGGGACA-3, 5-CTAAGGCCAACCGTGAAAAG-3. β-actin was used as 
housekeeping gene. For quantitative RT-PCR a final concentration of 500 nmol/L for each 
primer was used. Primers were designed to have a similar amplicon size and similar 
amplification efficiency as required for the utilization of the ∆∆Ct method to compare gene 
expression. Experiments were performed at least five times for each different preparation. 
mRNA levels of LMMP preparations from ABX or COMT mice were expressed as the 
percentage variation versus values obtained in non-antibiotic-treated (CNTR) and WT 
preparations, respectively. GDNF mRNA levels were analyzed in collaboration with the 
research group directed by Prof. Ignazio Castagliuolo, Department of Molecular Medicine, 
University of Padova. Total RNA was obtained from homogenized LMMP of TLR2-/- mice, ABX 
or ABX/Pam3-CSK4-treated mice (and respective controls) as previously described (Brun et al., 
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2013). Oligonucleotides used for qRT-PCR were: GDNF, 5’-TCCAACTGGGGGTCTACG-3’; 5’-
GACATCCCATAACTTCATCTTAGA-3’; Gadph: 5’-GAGGATCCTTCTGGGAGTTTTT-3’; 5’-
TAGCGAATGGGTGGATTTTC-3’. Expression of each mRNA was normalized to the level of the 
housekeeping gene Gapdh.  
Flow cytometry 
Flow cytometry experiments were performed in collaboration with the research group 
directed by Prof. Ignazio Castagliuolo, Department of Molecular Medicine, University of 
Padova. LMMP preparations, isolated from WT mice, were finely cut and incubated in 
collagenase type II (14 mg/ml, Gibco, Italy) and protease type I (10 mg/ml, Sigma, Italy) for 5 
min at 37°C in Hanks Balanced Salt Solution (HBSS, Euroclone, Italy) and then at 37°C for 15 
min in Krebs solution. Following enzymatic inactivation, cells were further dissociated by 
passing through a Pasteur pipette, filtered through a cell strainer and centrifuged at 900 g for 5 
min. LMMP-derived cell suspension was then analyzed with flow cytometry, as previously 
described (Brun et al., 2013). Briefly, cells (106) were incubated with the permeabilization 
buffer (PBS containing 0,2 % Triton-X100 (eBioscience, Italy) for 20 min at 22°C. After rapid 
washes in PBS-BSA 0.5 %, freshly isolated cells were treated with appropriate combination of 
antibodies diluted in permeabilization buffer added with 0,5 % BSA, for 30 minutes. For the 
detection of TLR2, cells were incubated with the primary antibody listed in Table 3.3. After 
washes, cells double-labeled for TLR2 and F4/80, CD31, GFAP and HuC/D were incubated with 
the appropriate secondary antibodies listed in Table 3.4, for 30 minutes in the dark. In parallel, 
controls were stained using only corresponding secondary or isotypic antibodies, listed in 
Table 3.4. Therefore, single-cell suspensions were subjected to flow cytometry analysis which 
was performed using a FACSCalibur based on CellQuest software (Becton Dickinson), as 
previously described (Brun et al., 2013). 
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Table 3.3. Characteristics of the primary antibodies used in the flow cytometry. 
 
 
 
 
 
 
. 
 
 
Table 3.4. Characteristics of the secondary and isotypic antibodies used in the flow cytometry. 
Statistical Analysis 
All results are reported as mean ± standard error of the mean (SEM), except for the geometric 
center, which is presented as median and range (minimum-maximum). Statistical significance 
was determined Statistical significance was calculated with the unpaired Student's t test or the 
1-way analysis of variance with Newman-Keuls post-hoc test for multiple variables, or the non-
parametric Mann–Whitney's U-test for independent variables using GraphPad Prism software 
(GraphPad Software Inc, La Jolla, USA). The differences between groups were considered 
significant at P-value <0.05 (Brun et al., 2013). 
 
ANTIGEN (HOST) CLONE SOURCE DILUTION 
HuC/D (mouse) polyclonal Merck Millipore 1:100 
GFAP (mouse) GA5 Merck Millipore 1:400 
CD31 (rat) MEC 13.3 BD Pharmingen 1:200 
F4/80 (rat) CI:A3-1 Abcam 1:100 
Α-smooth muscle actin,SMA 
(mouse) 
1A4 Cy3 conjugate Sigma Aldrich 1:50 
CD3 (mouse) 
DaA3 FITC-
conjugate 
Immuno Tools 1:100 
TLR2 (rabbit) H-175 
Santa Cruz 
Biotechnology 
1:100 
ANTIGEN (HOST) CLONE SOURCE DILUTION 
goat anti-rabbit IgG 
Rhodamine-
conjugate 
Chemicon 1:100 
goat anti-mouse IgG FITC-conjugate Chemicon 1:400 
rabbit anti-rat 
Alexa Fluor 488-
conjugate 
Invitrogen 1:200 
rat IgG isotype 
Alexa Fluor 488-
conjugate 
Biolegend 1:100 
goat IgG isotype 
Alexa Fluor 488-
cojugate 
Biolegend 1:200 
rat IgG isotype PE/Cy7-cojugate Biolegend 1:200 
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MATERIALS 
SUBSTANCE SOURCE 
Acetylthiocholine iodide Sigma-Aldrich, Italy 
Ampicillin Sigma-Aldrich, Italy 
Atropine sulfate Sigma-Aldrich, Italy 
β-NADPH Sigma-Aldrich, Italy 
Bovine serum albumin Sigma-Aldrich, Italy 
CaCl2∙2H2O Merck, Italy 
Carbamoylcholine chloride Sigma-Aldrich, Italy 
Collagenase type II Gibco, Italy 
Copper sulfate pentahydrate Sigma-Aldrich, Italy 
D-glucose anhydrous Sigma-Aldrich, Italy 
DNase Free Ambion, Italy 
Dulbecco's Modified Eagle's Medium  
Ethopropazine hydrochloride Sigma-Aldrich, Italy 
Fluorescein isothiocyanate–dextran 70.000 Da Sigma-Aldrich, Italy 
Glycine Sigma-Aldrich, Italy 
Guanethidine Sigma-Aldrich, Italy 
KCl Carlo Erba, Italy 
KH2PO4 Carlo Erba, Itay 
MgSO4∙7H2O Sigma-Aldrich, Italy 
Metronidazol Sigma-Aldrich, Italy 
Mounting Medium Sigma-Aldrich, Italy 
Na2HPO4 Merck, Italy 
Na2S Sigma-Aldrich, Italy 
NaCl Carlo Erba, Italy 
NaHCO3 Carlo Erba, Italy 
Neomycin Sigma-Aldrich, Italy 
NH4Cl Sigma-Aldrich, Italy 
Nitroblue tetrazolium Sigma-Aldrich, Italy 
Nω-nitro-L-arginina metil estere cloridrato Sigma-Aldrich, Italy 
OXPAPC InvivoGen, Italy 
Pam3CysSerLys4 InvivoGen, Italy 
Paraformaldehyde 8% Aqueous solution Electron Microscopy Sciences, Italy 
Power Sybr Green Universal PCR Master Mix  Applied Biosystems, Italy 
Protease type I Sigma-Aldrich, Italy 
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Sodium Acetate trihydrate Sigma-Aldrich, Italy 
Sodium merthiolate Sigma-Aldrich, Italy 
Sodium sulfide nonahydrate Sigma-Aldrich, Italy 
Triton X-100 Sigma-Aldrich, Italy 
TRIzol  Invitrogen, Italy 
Vancomycin Pharmatex Italia S.r.l. 
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4. RESULTS 
4.1 Toll-Like Receptor 2 in murine small intestine 
Toll-like receptors (TLRs), a subgroup of pattern-recognition receptors (PRRs), play a key role in 
the maintenance of symbiosis between gut microbiota and the mammalian host (Kabouridis 
and Pachnis, 2015), protecting against microbial infection as well as controlling tissue integrity 
under physiological and pathological conditions (Rakoff-Nahoum et al., 2004). TLR-derived 
signaling is required for proper development of CNS (Rolls et al., 2007) and, recently, TLR4 was 
discovered to be expressed in the ENS where has been shown to regulate murine 
gastrointestinal motility and promote the survival of enteric neurons (Anitha et al., 2012).  
4.1.1 Expression of TLR2 in ileal neuromuscular layer  
Since the presence of TLRs is reported in tissues not directly exposed to microbial products (i.e. 
CNS), we firstly evaluated the expression of TLR2 in the ileum by confocal microscopy. 
Immunohistochemical analysis performed on ileal frozen sections revealed that TLR2 was 
expressed in smooth muscle layers of WT mice (Figure 4.1A, upper panel), but there was no 
staining for the protein in TLR2-/- mice. We also observed the distribution of TLR2 in cells 
expressing the neurofilament protein peripherin, indicating the presence of this receptor in 
myenteric neuronal cells (Figure 4.1B).  
 
 
 
 
 
 
 
Figure 4.1. Expression of TLR2 protein in the ileal neuromuscular layers of WT mice. Panel A: Dual-label 
immunohistochemistry showing expression of TLR2 (green) and peripherin (red, cytoskeletal neuronal 
marker) proteins in ileal frozen cryosections from WT (upper panel) and TLR2
-/-
mice (lower panel). Cell 
nuclei were stained with TOTO-3. Scale bar = 22 µm. For each antigen, a single optical confocal section is 
shown. Panel B: Enlarged view of peripherin
+
 and TLR2
+
 cells in LMMP from WT mice from boxed area in 
merge panel. Scale bar = 12.5 µm. 
A B 
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By performing multiparameter flow cytometry staining of cells dissociated from longitudinal 
muscle-myenteric plexus (LMMP) of WT mice, TLR2 expression was detected on cells co-
expressing the pan neuronal marker HuC/D and glial fibrillary acid protein (GFAP, glial cells; 
Figures 4.2A and B). TLR2 expression was also observed in smooth muscle cells labeled for -
smooth muscle actin (α-SMA) protein, in endothelial cells and macrophages stained for CD31 
and F4/80 antigens, respectively, whereas was not revealed in CD3+ T-cells (Figures 4.2A and 
B). These findings suggest that ENS cell populations have the potential to respond directly to 
stimuli derived from the microbial flora throughout TLR2-mediated signaling (Barajon et al., 
2009). 
 
 
 
 
 
 
 
 
 
Figure 4.2. Distinct cell populations of the small intestine express TLR2. Expression of TLR2 in HuC/D
+
, 
glial fibrillary acidic protein
+
 (GFAP), -smooth muscle actin
+
 (α-SMA), CD31
+
, F4/80
+
 and CD3
+ 
cells 
harvested from LMMP of WT mice and analyzed by flow cytometry. For each LMMP, 10
6
 cells were 
collected. Panel A: Representative dot plots for each experiment are reported. Panel B: The histogram 
shows the percentage of double-positive cells for each population subset (n=6 per group). *p<0.05 vs 
respective negative control (isotype). 
4.1.2 Lack of TLR2 results in altered architecture of myenteric plexus 
Since TLRs signaling play a well recognized role in regulation of postnatal neuronal plasticity 
and TLR2 has been implicated in differentiation of neural stem/progenitor cells into neurons in 
the brain (Rolls et al., 2007), this analysis aimed to assess the impact of TLR2 absence on ENS 
development in mice. Histological assessment showed a conserved ileal architecture in TLR2-/- 
mice together with comparable levels of inflammatory mediators between TLR2-/- and WT mice 
(Brun et al., 2013, data not shown).  
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Whole mount immunohistochemistry, performed on LMMP preparations, revealed an altered 
distribution of peripherin in myenteric neurons of TLR2-/- mice (Figure 4.3), associated with a 
significant reduction in the number of HuC/D+ neurons and S100β+ EGCs (-25.6±15% and -
38.5±8% respectively, p<0.05; Figures 4.4A, B and C). The abnormal distribution of peripherin, 
a neuronal intermediate filament involved in the developing nervous system (Rauch et al., 
2006), together with the reduced expression of glial regulatory protein S100β as well as the 
reduced number of HuC/D+ cells, and S100β+ EGC, suggests that TLR2 signaling influences 
enteric neurogenesis and neuroplasticity by controlling both enteric neuronal and glial cells 
homeostasis.  
Considering the strong impact of the main inhibitory neurotransmitter nitric oxide (NO) on 
intestinal motility, the distribution and expression of neuronal nitric oxide synthase (nNOS) 
were analyzed in myenteric ganglia of mice lacking TLR2 protein. Whole mount 
immunohistochemistry showed an altered distribution of nNOS immunoreactivity in myenteric 
plexus of TLR2-/- mice, evidenced by the significant reduction of nNOS+ neurons in transgenic 
mice compared with WT (-29.5±4%, p<0.05; Figures 4.4D and E). 
Acetylcholinesterase (AChE) is the enzyme involved in catalyzing the hydrolysis of the 
excitatory neurotransmitter acetylcholine in choline and acetic acid, thus playing an essential 
role in cholinergic neurotransmission (Moore and Johnson, 2005; Anitha et al., 2006; Anitha et 
al., 2012). AChE  stained fibers were significantly decreased in TLR2-/- mice as compared with 
WT (Figure 4.4F), reflecting a dysfunction of the cholinergic system. Overall, these data 
support the view that intestinal TLR2 influences neuronal network integrity and neurochemical 
coding controlling gastrointestinal functions.  
 
 
 
 
 
 
 
Figure 4.3. Absence of TLR2 signaling perturbs myenteric plexus structure. Confocal microphotographs 
showing the distribution of peripherin (red, neuronal cytoskeleton marker) in ileal LMMP whole mount 
preparations from TLR2
-/- 
and WT mice (n=5). Scale bar = 22 µm.  
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. TLR2 signaling influences myenteric plexus architecture and neurochemical coding. 
Immunofluorescence analysis of LMMP whole mount preparations from WT and TLR2
-/-
 mice double-
labeled for pan-neuronal marker HuC/D (green), glial cells marker S100β, (red, Panel A), neuronal nitric 
oxide synthase protein (nNOS, red, panel D). Cell nuclei were stained with TOTO-3 (Panel A). Scale bars = 
44 µm in panel A and 22 µm in panel D. HuC/D
+
 and nNOS
+
 neurons (Panel B and E, respectively) and 
S100β
+
 glial cells (Panel C) per mm
2
 were quantified in LMMP whole-mount preparations of WT and 
TLR2
-/- 
mice (n=5). *p<0.05 vs WT. Representative photographs of AChE+ neurons and fibers; distribution 
and percentage changes in the number of the AChE
+
 fibers (Panel F) in whole mount preparations of 
ileum LMMPs from TLR2
-/-
 and WT mice (n=4). Scale bar = 300 µm. **p<0.01 vs WT. 
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4.1.3 TLR2-/- mice experience gastrointestinal motor dysfunction 
Since the enteric neural network architecture is altered in TLR2-/- mice, the gastrointestinal 
function was evaluated by performing in vitro contractility experiments. Isolated ileum 
segments of TLR2-/- mice, mounted vertically in organ bath, displayed abnormal excitatory 
neurotransmission following electric field stimulation (EFS). TLR2-/- mice showed a significant 
increase of EFS-elicited contractions (+81±8.6, p<0.01 at 10Hz; Figure 4.5), which up to 20 Hz is 
mediated by neuronal cholinergic neurotransmission as confirmed by their sensitivity to 
tetrodotoxin and to the muscarinic receptor blocker atropine (data not shown). 
 
 
 
 
 
 
 
 
Figure 4.5. Altered gastrointestinal motor function in TLR2
-/-
 mice. Electric field stimulation (EFS) elicited 
contractions (2-50 Hz, 40 V) in ileum segments of WT and TLR2
-/-
 mice. Data are reported as mean ± SEM 
(n=8) and are expressed as g tension/g dry tissue weight (g/g). **p<0.01 vs WT. 
 
In a second series of experiments, gastrointestinal transit was monitored in vivo using FITC-
dextran, to evaluate its distribution in the intestinal tract (small and large intestine). Sixty 
minutes after oral administration of FITC-labeled dextran, TLR2-/- mice exhibited an accelerated 
intestinal transit compared to WT (GCTLR2
-/- =8.1, range: 7.0-8.75 vs GCWT = 6.55, range: 5.8-
7.15, p<0.01; Figures 4.6A and B). Our findings indicate that TLR2 absence in ENS induces 
changes in the neuromuscular function, which may partly be responsible for altered intestinal 
motility.  
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Figure 4.6. Altered gastrointestinal motor function in TLR2
-/-
 mice. Panel A: Relative distribution of 
nonabsorbable fluorescein isothiocyanate (FITC) labeled dextran in the stomach (Sto), small bowel (Sb 1-
8), cecum (Cec), and colon (Col) in WT mice compared with TLR2
-/-
 mice. Panel B: Geometric centre (GC) 
of nonabsorbable FITC-dextran in CNTR and TLR2
-/-
mice. Data are reported as the mean ± SEM (n=6) for 
panel A and as median, minimum, maximum, upper and lower quartiles for panel B. **p<0.01 vs WT. 
4.1.4 TLR2-mediated intestinal motility changes are hematopoietic cell-independent  
To verify that TLR2-dependent functional anomalies are regulated by means of a 
hematopoietic cell-independent mechanism, we generated bone marrow chimeric mice from 
WT. As shown in Figure 4.7, EFS-induced contractions were similar in WT mice given either WT 
or TLR2-/- bone marrow, as well as in TLR2 mice receiving either TLR2-/- or WT bone marrow, 
demonstrating that the absence of TLR2 signaling in non hematopoietic cells causes the 
structural and functional anomalies observed in the ENS.  
 
 
 
 
 
 
Figure 4.7. TLR2-dependent ENS anomalies are hematopoietic cell-independent. Excitatory response of 
ileal segments from WT, WT→WT and TLR2
-/-
→WT mice (Panel A) and TLR2
-/-
, TLR2
-/-
→TLR2
-/-
, 
WT→TLR2
-/-
 mice (Panel B) induced by electrical field stimulation (EFS) (2-50 Hz, 40 V). Data are 
reported as mean ± SEM (n=8 per group) and are expressed as g tension/g dry tissue weight (g/g). 
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4.1.5 TLR2 signaling influences GDNF production in the muscularis externa layer of 
murine ileum 
Given the well recognized role of glial derived neurotrophic factor (GDNF) in the proper 
development and maintenance of ENS structural and functional integrity (Gershon, 2010; 
Wang et al., 2010), the expression of this neurotrophic factor was examined. As shown in 
Figure 4.8, TLR2-/- mice displayed a decrement in mRNA transcripts (-70.8±0.001%, p<0.05; 
Figure 4.8A) and immunoreactivity of GDNF in ileal muscle layers (Figure 4.8B). 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. TLR2 signaling pathway influences GDNF signaling. Panel A: Quantitative reverse 
transcription polymerase chain reaction (RT-PCR) analysis of GDNF mRNA in LMMP from WT and TLR2
-/-
 
mice (n = 6 per group). *p<0.05 vs WT. Panel B: GDNF immunostaining in ileum of WT and TLR2
-/-
mice. 
Scale bars = 75 µm. 
4.1.6 GDNF administration ameliorates ENS defects in TLR2-/- mice 
To demonstrate that ENS abnormalities in TLR2-/-mice are consequent to insufficient levels of 
GDNF, the neurotrophic factor was administered in vivo to TLR2-/- mice for 7 days. rGDNF 
supplementation significantly improved the contractile abnormalities in ileum segments, as 
demonstrated by EFS-elicited response, which was comparable between WT mice and TLR2-/- 
mice treated with rGDNF (Figure 4.9A). Administration of rGDNF also ameliorated 
gastrointestinal transit (GCTLR2
-/-
+GDNF =6.9, range: 5.8-7.9 vs GCWT = 6.55, range: 5.8-7.15, 
Figures 4.9B and C) and, moreover, prevented the loss of nitrergic neurons in myenteric 
ganglia, bringing the number of nNOS+ neurons related to the WT, as shown by confocal 
immunohistochemistry in Figures 4.10A and B. 
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Figure 4.9. GDNF administration prevents ENS abnormalities in TLR2
-/-
 mice. Panel A: EFS-elicited 
contractions in ileum segments of WT and TLR2
-/-
mice treated with rGDNF or vehicle. Data are reported 
as mean ± SEM (n=6 per group) and are expressed as g tension/g dry tissue weight (g/g).**p<0.01 vs 
WT; °°p<0.01 vs TLR2
-/-
. Panel B: Gastrointestinal distribution of non absorbable FITC-labeled dextran 60 
minutes after oral administration in stomach (Sto), small bowel segments (Sb1-8), caecum (Cec) and 
colon (Col) of TLR2
-/-
 mice treated with either rGDNF or vehicle. Panel C: Calculation of the geometric 
center (GC) of the relative FITC-dextran distribution through the GI tract of TLR2
-/-
 mice treated with 
either rGDNF or vehicle compared to WT mice. Data are reported as the mean ± SEM (n=6) for panels A 
and B, and as median, minimum, maximum, upper and lower quartiles for panel C. **p<0.01 vs WT; 
°°p<0.01 vs TLR2
-/-
. 
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Figure 4.10. rGDNF administration prevents loss of nNOS
+
 neurons in myenteric plexus of TLR2
-/-
 mice. 
Panel A: Immunofluorescence analysis of LMMP from WT and TLR2
-/-
 mice treated with either rGDNF or 
vehicle (n=5 per group). Myenteric ganglia were labeled for HuC/D (green) and nNOS (red) antigens. 
Scale bars = 44 µm. Panel B: Number of nNOS
+
 neurons per mm
2
 in LMMP of WT and TLR2
-/-
 mice 
treated with either rGDNF or vehicle (n=5 per group). *p<0.05 vs WT. 
 
4.2 Antibiotic-mediated microbiota depletion alters ENS structure and 
function in adolescent mice 
The ENS network coordinates the major functions of the gastrointestinal tract. As in the case of 
CNS, the development of ENS takes place within a constantly changing environment which, 
after birth, culminates in the establishment of a dynamic and complex microbial ecosystem 
(Borre et al., 2014; Wopereis et al., 2014; Kabouridis et al, 2015). How such changes affect ENS 
development and its subsequent function throughout life is still inadequately explored. This 
part of the study aimed to evaluate the specific contribution of the microbiota to ENS 
development and gastrointestinal function by depleting gut microflora using a combinations of 
antibiotics administered to WT mice during their adolescence. 
4.2.1 Antibiotic-induced microbiota depletion produces a germ free-like phenotype 
in adolescent mice 
Mice born and raised in a germ-free environment possess numerous characteristics 
distinguishing them from mice living in a conventional microbiological environment. 
Macroscopically, germ-free mice display hypotrophic secondary lymphoid organs, enlarged 
ceca, and reduced epithelial cell turnover (Smith et al., 2007). Treatment with broad spectrum 
antibiotics for 14 days successfully depleted gut microbiota (Brun et al., 2013, data not shown), 
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determining a marked enlargement in caecum (+92±0.1%, p<0.01; Figures 4.11A and B) that 
was associated with a threefold increase of its weight (p<0.05; Figure 4.11C). These anomalies 
provided evidence that microbiota depletion induces in mice phenotypic characteristics similar 
to those found in germ-free mice (Reikvam et al., 2011). 
 
 
 
 
 
 
 
 
Figure 4.11. Antibiotic-induced microbiota depletion induces cecal enlargment. Panel A: Representative 
photographs of murine cecum-colon tract; cecal area (number of pixels, arbitrary units, A.U.) and weight 
(Panel B e C) in in vivo antibiotic-treated (ABX) and control (CNTR) mice (n=4). **p<0.05;***p<0.01 vs 
CNTR. 
4.2.2 Depletion of gut microbiota causes morphological abnormalities in the ENS 
architecture  
For a more comprehensive analysis of the impact of gut microbiota depletion on ENS 
homeostasis, the structural integrity of enteric neurons and ECGs was evaluated using confocal 
microscopy. The immunoreactivity for HuC/D protein, a pan-neuronal marker involved in 
sprouting and regenerations of neurons (De Giorgio et al., 2003) was significantly increase in 
antibiotic-treated (ABX) mice compared to control (CNTR) ones (+31±0.08%, p<0.01; Figures 
4.12.A and B). The distribution of GFAP, the major component of intermediate filaments in the 
cytoskeleton of glial cells, was then analyzed. Confocal microphotographs showed a significant 
reduction of GFAP immunoreactivity in ileal samples of ABX mice (-50.3±0.08%, p<0.01; Figures 
4.12A and C). Moreover, EGCs, which are located along myenteric ganglia, were also observed 
to have distorted GFAP+ processes in mice after antibiotic treatment (Figure 4.13A). Changes in 
GFAP expression during glial cell differentiation, inflammation and injury have been associated 
to the functional state of glial cells (Cirillo et al., 2011a), suggesting that EGC homeostasis is 
dependent on microbiota health and composition.  
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Figure 4.12. Depletion of gut microbiota causes morphological abnormalities in the ENS architecture. 
Panel A: Confocal microscopy analysis of the distribution of pan-neuronal marker HuC/D (yellow) and 
glial marker GFAP (magenta) in ileal cryosections from CNTR and ABX mice (n=4). Nuclei were stained 
with TOTO-3. Scale bar: 22 μm. LM, longitudinal muscle; CM, circular muscle; MG, myenteric ganglia; 
ML, mucosal layer. Panel B: Levels of HuC/D fluorescence intensity, expressed as arbitrary units (AU), in 
the myenteric ganglia of the ileal neuromuscular layer from ABX and CNTR mice **p < 0.01 versus CNTR. 
Panel C: Levels of GFAP fluorescence intensity, expressed as arbitrary units (AU), in the myenteric 
ganglia of ileum from ABX and CNTR mice **p< 0.01 versus CNTR. 
 
Similar to the CNS astrocytes, ECGs physiologically express the protein S100β, a small diffusible 
calcium-binding protein, that exerts either trophic or toxic effects depending on its levels in 
the extracellular milieu (Cirillo et al., 2011a). S100β immunoreactivity was found to be 
significantly increased in the ileal myenteric plexus of ABX mice (+123.2±0.05%, p<0.001; 
Figures 4.13A and B). In parallel, the distribution of nNOS protein in microbiota-depleted mice 
was analyzed. The immunoreactivity for nNOS was significantly enhanced (+31.4±0.08%, 
p<0.05, Figures 4.14A and B) in ileal sections from ABX mice compared to controls. These 
abnormalities in the expression of both nNOS and S100β proteins, following microbiota 
depletion, are indicative of a possible microinflammatory state that can possibly trigger ENS 
neuropathy (Aubé et al., 2006; Cirillo et al., 2009). 
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Figure 4.13. Panel A: Double-staining immunohistochemistry showing the distribution of S100β 
(magenta, glial calcium-binding protein) and HuC/D (yellow, pan-neuronal marker) proteins in ileal 
frozen cryosections from ABX and CNTR mice (n=5). Cell nuclei were stained with TOTO-3. For each 
antigen, a single optical confocal section is shown. Scale bar = 22 µm. LM, longitudinal muscle; CM, 
circular muscle; MG, myenteric ganglia; ML, mucosal layer. Panel B: Levels of S100β fluorescence 
intensity, expressed as arbitrary units (AU), in the myenteric ganglia of ileum from ABX and CNTR mice 
***p<0.001 versus CNTR. 
 
 
 
 
 
 
 
 
Figure 4.14. Panel A: Double-staining immunohistochemistry showing the distribution of neuronal nitric 
oxide synthase (nNOS, magenta; marker for nitrergic neurons) and HuC/D (yellow, pan-neuronal 
marker) proteins in ileal frozen cryosections from ABX and CNTR mice (n=5). Cell nuclei were stained 
with TOTO-3. For each antigen, a single optical confocal section is shown. Scale bar = 22 µm. LM, 
longitudinal muscle; CM, circular muscle; MG, myenteric ganglia; ML, mucosal layer. Panel B: Levels of 
nNOS fluorescence intensity, expressed as arbitrary units (AU), in the myenteric ganglia of ileum from 
ABX and CNTR mice *p< 0.05 versus CNTR. 
4.2.3 Antibiotic-induced microbiota depletion alters ileal neuromuscular contractility 
The effect of ABX treatment on intestinal neuromuscular function was examined in vitro by 
measuring changes in muscle tension by means of the isolated organ bath technique. To 
evaluate muscle responsiveness, ileal segments of ABX and CNTR mice were exposed to the 
non selective cholinergic receptor agonist carbachol (CCh), added cumulatively to organ baths 
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(0.01–100 μmol/L) in order to obtain a concentration-response curve. A significant downward 
shift of the concentration-response curve to CCh and a consequent decrease in Emax occurred 
in ABX (-52±6%, p<0.01; Figure 4.15A) compared with CNTR group. In a second series of 
experiments, contractions were evoked by addition of the depolarizing agent KCl (60 mM) to 
ileal preparations from ABX and CNTR mice. The neuromuscular response elicited by KCl-
induced depolarization was significantly decreased in ABX mice (-28±8%, p0.01; Figure 4.15B) 
compared with CNTR mice. 
 
 
 
 
 
 
 
 
Figure 4.15. Effect of in vivo ABX-treatment on carbachol and KCl-induced intestinal contractions. 
Concentration–response curves for carbachol (0,001-100 M) obtained in isolated ileal preparations 
from ABX and CNTR mice (Panel A) and excitatory effect elicited by KCl 60 mM (Panel B). Data are 
reported as mean ± SEM (n=8) and are expressed as g tension/g dry tissue weight (g/g). **p<0.01 vs 
CNTR. 
 
To determine whether the differences in ileal contraction between ABX and CNTR mice were 
associated with alterations in neuromuscular function, we evaluated ileal contractility 
following EFS with increasing frequencies and constant voltage (2–40 Hz, 40 V). Altered 
excitatory neurotransmission in ABX mice was shown by decreased EFS-elicited contractions 
with a significant reduction of 10 Hz-neuronal cholinergic response (-62±7%, p<0.01; Figure 
4.16) compared to CNTR mice.  
To evaluate the impact of the main inhibitory neurotransmitter NO on intestinal motility, in a 
third series of experiments, atropine (1 µM) and guanethidine (1 µM) were added to Krebs 
solution, in order to block cholinergic and adrenergic transmission (so called NANC conditions), 
respectively. NANC-stimulation, evoked by EFS at 10 Hz, was performed with or without the 
pan-NO synthase inhibitor Nω-nitro-l-arginine methyl ester (L-NAME, 100 µM).  
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Figure 4.16. Neuromuscular excitatory response induced by EFS (2-50 Hz) in CNTR and ABX mice. Data 
are reported as mean ± SEM (n=8) and are expressed as g tension/g dry tissue weight (g/g). **p<0.01 vs 
CNTR. 
EFS-induced NANC stimulation at 10 Hz caused a marked relaxation, measured as AUC, that 
results significantly greater in ileal preparations of ABX mice compared to CNTR mice 
(+144±40%, p<0.05; Figure 4.17). Addition of L-NAME significantly blocked EFS (10Hz)-evoked 
NANC ileal relaxation in ileal samples of CNTR mice, however, in ABX mice this response was 
only partially abolished by the NOS inhibitor (-64±10%, p<0.001; Figure 4.17). Our findings 
suggest that the depletion of intestinal microbiota influences inhibitory neurotransmission not 
only the one mediated by nitrergic neurotransmission but also those controlled by other 
inhibitory pathways (e.g. ATP or VIP), known to be involved in sustaining intestinal contractility 
function (Mulè and Serio, 2003; Zizzo et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Effect of in vivo ABX tretament on inhibitory contractile responses. EFS (10Hz)-evoked 
NANC relaxation in presence or absence of L-NAME in ileal preparations from CNTR and ABX mice. Data 
are expressed as percentage of abolition of contraction (Area Under the Curve, AUC)/g dry tissue weight 
(n=8). *p0.05 vs CNTR; °°p<0.01, °°°p<0.001 vs respective control. 
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4.2.4 Gastrointestinal motor function is impaired in antibiotic-treated mice  
To evaluate gut motor function in vivo, the measurement of GI transit was performed. 
Antibiotic-mediated microbiota depletion determined a significant decrease of GI transit, as 
evidenced by the altered gut distribution of nonabsorbable FITC-dextran (Figure 4.18A). 
Moreover ABX mice displayed a half reduction of the geometric centre compared to CNTR 
mice (Figure 4.18B, GCABX=3.5, range: 2.9-4.0 vs GCCNTR=7.3, range: 6.2-7.9; p<0.01).  
 
 
 
 
 
 
 
 
 
Figure 4.18. Impaired gastrointestinal transit in ABX mice. Panel A: Gastrointestinal (GI) transit was 
measured as % of nonabsorbable FITC-dextran distribution in 15 gut segments, comprising stomach 
(Sto), small bowel (Sb 1–10), cecum (Cec), and colon (Col 1–3), 30 minutes after oral administration in 
CNTR and ABX mice (n=6). Panel B: Calculation of the geometric center (GC) demonstrated a significant 
alteration of GI transit in ABX compared to CNTR mice. Data are reported as the mean ± standard error 
of the mean (SEM; n=6) for panel A and as median, minimum, maximum, upper and lower quartiles for 
panel B. **p<0.01 vs CNTR.  
The delay of distribution of FITC-dextran throughout the GI tract of mice treated with ABX 
cocktail was reflected in corresponding changes in stool frequency and water content, which 
were determined from fecal pellets obtained during a 1 h-collection period. There was a 
significant reduction in stool frequency (-29.5±0.5%, p<0.01; Figure 4.19A) together with an 
increase in faecal water content (+35±7%, p<0.01; Figure 4.19B) in ABX mice compared to 
controls, indicating a possible state of constipation and alteration of intestinal permeability as 
a result of antibiotic treatment. 
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Figure 4.19. Changes in stool frequency and water content after ABX treatment. Panel A: Pellet 
frequency per hour was assessed in CNTR and ABX
 
mice (n=10). Panel B: CNTR and ABX stool water 
content was determined by calculating the water content in faecal pellets collected over a one hour 
period (n=12). **p<0.01 vs CNTR.  
 
4.2.5 Antibiotic-induced microbiota depletion influences ENS neurochemical coding 
To further examine the role of gut microbiota in maintaining the ENS neurochemical code, we 
assessed the functional integrity of the myenteric plexus by performing acetylcholinesterase 
and NADPH-diaphorase biochemical staining in ileal LMMP whole mount preparations of ABX 
mice (Anitha et al., 2012; Brun et al., 2013).  
Acetylcholinesterase (AChE) is the enzyme involved in catalyzing the hydrolysis of the 
excitatory neurotransmitter acetylcholine in choline and acetic acid, thus playing an essential 
role in cholinergic neurotransmission (Moore and Johnson, 2005; Anitha et al., 2006; Anitha et 
al., 2012). The number of AChE+ fibers was increased in LMMP whole mount preparations of 
ABX (+37±9%, p<0.001; Figure 4.20) compared with CNTR mice suggesting that antibiotic-
induced dysbiosis may affect intestinal excitatory neurotransmission.  
The NADPH-diaphorase (NADPH-d) biochemical staining reveals the NO synthase activity in the 
myenteric plexus of CNTR and ABX mice (Anitha et al., 2006; Anitha et al., 2012). The 
localization of NADPH-d activity was detected by blue formazan precipitate that was formed by 
the enzyme from NBT in the presence of β-NADPH. Exposure to the ABX treatment did not 
affect the number of NADPH-d+ cells that was comparable to CNTR (Figure 4.21).  
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Figure 4.20. Antibiotic-induced dysbiosis alters the distribution of acetylcholinesterase (AChE)
+
 neurons 
and fibers in the ileal ENS. Representative photographs of AChE
+
 neurons and fibers distribution (panel 
A) and percentage changes in the number of the AChE
+
 fibers (panel B) in whole mount preparations of 
ileum LMMPs from ABX and CNTR mice (n=4). Scale bar = 300 m. ***p<0.001 vs CNTR. 
 
 
 
 
 
 
 
 
 
Figure 4.21 Influence of in vivo antibiotic-treatment on NADPH-d
+
 fibers distribution in ileal myenteric 
plexus. Panel A: Representative microphotographs showing the distribution of the NADPH-d
+
 fibers in 
the ENS of CNTR and ABX mice. Scale bar = 200 µm. Panel B: Percentage changes in the number of 
NADPH-d
+
 fibers in whole mount preparations of CNTR and ABX mice (n=5). 
4.2.6 Antibiotic-induced microbiota depletion increases mRNA of GluN1 subunit 
expression  
The aminoacid glutamate via the activation of the ionotropic AMPA and NMDA receptors 
appears to play a pivotal role in the modulation of several neurotransmitters release as well as 
in the control of enteric motor parameters (Kirchgessner, 2001). In particular, NMDA receptors 
are involved in integrating the firing of specific peripheral neurons and amplifying nociceptive 
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signals. This process leads to central sensitization, which is characterized by enlarged neuronal 
receptive fields and hyperalgesia (Willert et al., 2004). Quantitative RT-PCR analysis showed a 
significant increase of mRNA levels of GluN1 subunit of NMDA receptor in ileal LMMP 
preparations from ABX mice compared to CNTR (+35±0.04%, p<0.01; Figure 4.22), indicating 
that changes in composition of gut microbiota can impact the glutamatergic transmission in 
the enteric neuronal circuitries leading to visceral hypersensitivity (Zhou et al., 2009).  
 
 
 
 
 
 
 
 
Figure 4.22. Antibiotic-induced microbiota depletion increases mRNA of GluN1 subunit expression. RT-
PCR quantification of GluN1 transcripts performed in ileal LMMP preparations of ABX (black bar) and 
CNTR mice (white bar). Values are expressed as mean ± SEM (n=5) of the percentage variation of 
relative gene expression with respect to relative control. The relative gene expression was determined 
by comparing 2
-ΔΔCt
 values normalized to β-actin. **p<0.01 vs CNTR. 
4.2.7 TLR2 stimulation partially corrects ENS anomalies caused by antibiotic-induced 
microbiota depletion 
As previously reported in this study, disturbances in neurotrophic factor signaling, such as 
GDNF, can determine morphofunctional abnormalities of ENS and TLR2 signaling is required 
for adequate GDNF expression in the gut. Antibiotic-induced microbiota depletion determined 
a decrease of mRNA levels of GDNF (-89±0.001%, p<0.05; Figure 4.23A) together with a 
reduction of its immunoreactivity, as shown in Figure 4.23B. Administration of Pam3CSK4, a 
TLR2 bacterial-derived ligand, to ABX mice during the second week of ABX treatment 
determines a 7-fold increase of GDNF mRNA levels in LMMP preparations (p<0.001; Figure 
4.24A). Treatment with Pam3CSK4 also partially corrected anomalies in intestinal contraction 
of ABX mice, as shown in Figure 4.24B, confirming that ENS integrity relies on gut microbiota-
TLR2-GDNF axis. 
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Figure 4.23: Antibiotic-induced microbiota depletion influences GDNF expression. Panel A: Quantitative 
RT-PCR analysis of GDNF mRNA in LMMP from WT mice treated for 14 days with or without antibiotics 
(ABX) (n=4 per group).*p<0.05 vs CNTR. Panel B: GDNF immunostaining in ileum of WT mice with or 
without antibiotics (ABX) for 14 days. Scale bar = 75 μm.  
 
 
 
 
 
 
 
 
 
 
Figure 4.24. Pam3CSK4 administration improves intestinal neuromuscular contractility in ABX mice via 
TLR2-mediated GDNF production. Panel A: Quantitative RT-PCR analysis of GDNF mRNA in LMMP from 
WT mice treated 14 days with antibiotics (ABX) with or without Pam3CSK4 supplemented daily during 
the second week of treatment with antibiotics (n=4 per group). *p<0.05 vs. CNTR, ***p<0.001 vs ABX. 
Panel B: Neuromuscular excitatory response induced by EFS (2-50 Hz) in CNTR, ABX and ABX mice 
treated daily with Pam3CSK4. Data are reported as mean ± SEM (n=8) and are expressed as g tension/g 
dry tissue weight (g/g). *p<0.01 vs CNTR, °p<0.05 vs ABX. 
 
4.2.8 OXPAPC inhibition of TLR2 and TLR4 signaling alters ileal neuromuscular 
contractility and influences ENS neurochemical code 
To evaluate the effect of inhibition of both TLR2 and TLR4-mediated signaling on the intestinal 
motor responses, WT mice at postnatal day 14 (P14) were treated with OXPAPC administered 
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intraperitoneally once a day for 1 week. At the end of the treatment, in vitro contractility 
studies were performed. Receptor-mediated response to carbachol, added cumulatively to 
organ baths (0.01–100 μmol/L), resulted significantly increased in OXPAPC-treated mice 
(+42±3.5%, p0.01; Figure 4.25A) compared to mice treated with vehicle. Moreover, 
frequency-response curve, obtained following electrical field stimulation (EFS) with increasing 
frequencies, was significantly greater in mice after OXPAPC administration (+88±10% at 10 Hz, 
p0.01 vs CNTR; Figure 4.25B), indicating that inhibition of TLR2 and TLR4 signaling can 
influence intestinal neuromuscular contractility. 
 
 
 
 
 
 
 
 
Figure 4.25. Effect of OXPAPC-mediated inhibition of TLR2 and TLR4 signaling on ileal neuromuscular 
contractility. Concentration-response curve to carbachol (Panel A) and excitatory response to electric 
field stimulation (EFS; Panel B) in isolated ileal segments from mice treated with OXPAPC and mice 
treated with vehicle (0.9% saline, CNTR). Data are reported as mean ± SEM (n=6 for group) and are 
expressed as g tension/g dry tissue weight (g/g). **p<0.01 vs CNTR.  
 
In order to assess whether OXPAPC-mediated inhibition of TLR2 and TLR4 signaling could 
change the distribution of the cholinergic neurons in myenteric ganglia, the biochemical 
staining of AChE was performed. The number of AChE+ fibers was increased in LMMP whole 
mount preparations of OXPAPC-treated mice (+29.5±1.2%, p<0.001; Figures 4.26A and B) 
compared to CNTR ones. These findings suggest that the blocking of the recognition of 
commensal microbial components by TLR2 and TLR4 can impact the integrity of ENS excitatory 
neuronal networks and consequently the intestinal function. 
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Figure 4.26. Influence of OXPAPC treatment on acetylcholinesterase
+
 fibers distribution in ileal 
myenteric plexus. Panel A: Representative microphotographs showing the distribution of 
acetylcholinesterase (AChE)
+
 fibers in the ENS of mice treated with either OXPAPC or vehicle. Scale bar: 
300 µm. Panel B: Percentage changes in the number of AChE
+
 fibers (n=5). ***p<0.001 vs CNTR  
4.3 CATECHOL-O-METHYLTRANSFERASE GENETIC REDUCTION 
INFLUENCES GI MOTILITY AND ENS STRUCTURE  
Intestinal functional disorders, such as irritable bowel syndrome (IBS), are characterized by 
abdominal discomfort more frequently in women and are often associated with a variety of 
psychiatric illness, ranging from anxiety and depression to obsessive-compulsive disorder. The 
etiology of these intestinal functional disorders is multi-factorial and has been ascribed to 
dysregulation of the brain-gut axis, hypothalamus-pituitary-adrenal (HPA) axis, altered 
gastrointestinal motility, visceral hypersensitivity, infectious factors, enhanced immunological 
reactivity, genetic susceptibility and psychosocial factors (Karling et al., 2011). The presence of 
a bidirectional communication system between CNS and ENS implies that both gut and brain 
are reciprocally able to influence each other via vagal and sympathetic afferent fibers 
(Fadgyas-Stanculete et al., 2014). The pathophysiological links between psychiatric symptoms 
and gut manifestation in IBS has not been yet fully understood but it has been proposed that 
changes in the endogenous pain modulation system, autonomic nervous system (ANS) and 
HPA axis together with altered catecholamine levels may each play a role (Fadgyas-Stanculete 
et al., 2014). Recently, genetic variation in COMT, the key enzyme responsible for 
catecholamine degradation (e.g. dopamine, epinephrine, and norepinephrine), has been 
shown to be associated with anxiety, behavior disorders, pain and IBS (Hall et al., 2015). A 
functional polymorphism of the COMT enzyme is the val158met. The val/val genotype results 
in a three to fourfold higher enzymatic activity compared with the met/met genotype, with the 
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val/met genotype exhibiting intermediate activity (Karling et al., 2011). Since visceral pain 
syndrome is associated to low COMT activity and this condition is one of the main symptoms 
of IBS, this part of the study aimed to explore the relationship between an altered COMT 
activity and gastrointestinal function using a model of genetic reduction of COMT enzyme. 
4.3.1 COMT reduced expression alters ileal structure 
Female mice heterozygous for COMT gene (COMT+/-) were used for the following experiments. 
Phenotypic histological analysis revealed no morphological differences between ileal sections 
from COMT+/- and WT female mice. However, hematoxylin-eosin stained sections showed a 
significant increase in muscle layer thickness between COMT+/- and WT mice (+87±0.01%, 
p<0.01; Figures 4.27A and B). 
 
 
 
 
 
 
 
 
Figure 4.27. Morphological analysis of full-tickness ileal samples from COMT
+/-
 and WT mice. Panel A: 
Representative ileal sections, stained with H&E, from COMT
+/-
 and WT mice (n=4). Scale bar: 25 μm. 
Panel B: Changes in tickness (arrow) of ileal tunica muscularis (arbitrary units, A.U.) in COMT
+/-
 mice 
(n=5). **p<0.01 vs WT.  
 
4.3.2 COMT reduced expression influences ENS neurochemical coding 
Along with the reported abnormalities of the ENS in various functional gastrointestinal motor 
disorders (Di Nardo et al., 2008), immunohistochemical analysis of LMMP whole mount 
preparations revealed an altered distribution of the immunoreactivity for GFAP and S100β in 
glial cells within the myenteric plexus of COMT+/- mice, whereas no difference in the βIII 
tubulin network was observed (Figure 4.28). 
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Figure 4.28. COMT genetic reduction perturbs myenteric plexus architecture. Representative confocal 
microphotographs showing the distribution of the glial markers GFAP (cyan) and S100β (magenta), and 
the neuronal marker βIII tubulin (green) in ileal whole mount preparations of WT and COMT
+/-
 mice 
(n=4). Scale bar = 22 μm. 
4.3.3 COMT+/- mice display abnormal gastrointestinal neuromuscular function 
The effect of COMT genetic reduction on gut neuromuscular function was examined in vivo by 
assessing gastrointestinal transit and in vitro by measuring tension changes in ileal segments. 
Gastrointestinal transit was assessed by measuring the distribution of nonabsorbable FITC-
labeled dextran from the stomach to the colon. COMT genetic reduction determined an 
altered gut distribution of the fluorescent probe, associated to a significant increase of 
gastrointestinal transit in COMT+/- mice compared to WT (Figures 4.29 A and B; GCCOMT
+/-=6.5, 
range: 5.7-7.5 vs GCWT 5.8, range: 4.9-6.4; p<0.05). 
 
 
 
 
 
 
 
Figure 4.29. Impaired gastrointestinal transit in COMT
+/-
 mice. Panel A: Percentage of the nonabsorbable 
FITC-dextran distribution in 15 gut segments, comprising stomach (Sto), small bowel (Sb 1–10), cecum 
(Cec), and colon (Col 1–3), 30 minutes after oral administration in WT and COMT
+/-
mice (n=6). Panel B: 
Calculation of the geometric center (GC) demonstrated a significant alteration of GI transit in COMT
+/-
 
compared to WT mice (n=6). Data are reported as the mean ± SEM for panel A and as median, 
minimum, maximum, upper and lower quartiles for panel B (n=6). *p<0.05 vs WT. 
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In in vitro contractility studies, ileal preparations were subjected to increasing concentrations 
of carbachol (a non selective cholinergic agonist) in order to underline anomalies in the 
receptor-mediated response. The maximal contractile response (Emax) resulted markedly 
reduced in COMT+/- mice (Emax=-41±8%, p<0.01, Figure 4.30A) with respect to the value 
obtained in WT mice. To study the influence of COMT genetic reduction on neuromuscular 
activity, the ileal preparations were subjected to KCl 60 mM. The registered depolarizing effect 
resulted significantly reduced (-38±5%, p<0.01; Figure 4.30B) in COMT+/- mice compared with 
WT. To determine whether the differences in muscle contraction between WT and COMT+/- 
mice were associated with alterations in neuromuscular function, we measured changes in 
muscle tension in response to the EFS. COMT genetic reduction determined changes in the 
neuronal contractile response with a significant reduction of the neuronal excitatory 
cholinergic contraction up to 20 Hz (-33±6% at 10 Hz, p<0.01; Figure 4.30C).  
 
 
 
 
 
 
 
 
 
Figure 4.30. COMT genetic reduction affects ileal neuromuscular contractility. Concentration–response 
curves to carbachol (CCh, Panel A), excitatory response to KCl 60 mM (Panel B) and EFS-induced 
contractions (Panel C) in isolated ileal segments from WT and COMT
+/-
 mice. Data are reported as mean 
± SEM and are expressed as g tension/g dry tissue weight (n=8). *p<0.01 vs WT. 
4.3.4 COMT reduced expression alters ileal neuromuscular inhibitory response 
Non-adrenergic, non cholinergic (NANC) inhibitory neurons play an important role in the 
regulation of GI motility, and NO is the major NANC inhibitory neurotransmitter of the GI tract. 
To evaluate the influence of COMT genetic reduction on inhibitory neurotransmission, in this 
series of experiments atropine (1 µM) and guanethidine (1 µM) were added to Krebs solution, 
in order to block cholinergic and adrenergic transmission (so called NANC conditions), 
respectively. EFS at 10 Hz was then performed with or without the pan-NOS inhibitor L-NAME 
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(100 µM). EFS-induced NANC stimulation at 10 Hz caused a marked relaxation, that resulted 
significantly greater in ileal preparations of COMT+/- mice compared to WT (+114±10%, p<0.05; 
Figure 4.31). Pretreatment of ileal samples with L-NAME significantly blocked EFS (10Hz)-
evoked NANC relaxation in WT mice, demonstrating its neuronal origin (Mulè and Serio, 2003). 
In COMT+/- mice the relaxation was partially block by the NOS inhibitor (-72±8%, p<0.05; Figure 
4.31) to suggest that the disturbances of catecholaminergic transmission due to low activity of 
COMT can affect not only nitrergic neurotransmission but also the release of other 
neurotransmitters inhibitors (eg ATP, VIP, or dopamine) involved in supporting intestinal 
motor function (Mulè and Serio, 2003; Zizzo et al., 2003; Li et al., 2006). 
 
 
 
 
 
 
 
 
Figure 4.31. Effect of COMT genetic reduction on inhibitory contractile responses. EFS (10Hz)-evoked 
NANC relaxation in presence or absence of L-NAME in ileal preparations from COMT
+/-
 and WT mice. 
Data are expressed as percentage of abolished contraction (AUC)/g dry tissue weight (n=8). *p<0.05 vs 
WT; °p<0.05, °°p<0.01 vs respective control. 
4.3.6 COMT reduced expression influences ENS neurochemical coding  
Given the functional alterations on both excitatory and inhibitory component of intestinal 
contractility in presence of a reduced COMT activity, the distribution of excitatory (i.e. 
cholinergic) and inhibitory (i.e. nitrergic) neurons in myenteric ganglia of COMT+/- mice was 
evaluated. Acetylcholinesterase biochemical staining revealed a significantly reduction of 
acetylcholinesterase+ neurons and fibers in whole mount preparations of LMMP of COMT+/- 
mice (-26±3%, p<0.01; Figure 4.32) compared with WT. Moreover, COMT genetic reduction 
determined an altered distribution of NADPH-d+ neurons with an increase of nNOS+ large and 
small fibers in transgenic mice (+41±5%, p<0.01; Figure 4.33), suggesting a role of the 
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catecholaminergic transmission in modulating ENS neurochemical code and thus gut motor 
function.  
 
 
 
 
 
 
 
Figure 4.32. Changes in the distribution of acetylcholinesterase
+
 fibers in the ENS of COMT
+/- 
mice. Panel 
A: Representative microphotographs showing the distribution of acetylcholinesterase (AChE
+
) fibers in 
the ENS of WT and COMT
+/-
 mice (n=4). Scale bar = 300 µm. Panel B: Percentage changes in the number 
of AChE
+
 fibers. ***p<0.01 vs WT.  
 
 
 
 
 
 
 
 
Figure 4.33. Influence of COMT genetic reduction on NADPH-d
+
 fibers distribution in ileal myenteric 
plexus. Panel A: Representative microphotographs of the distribution of NADPH d-stained neurons in 
ileal LMMP preparations from WT and COMT
+/-
 mice (n=4). Scale bar = 200 µm. Panel B Percentage 
changes in the number of NADPH-d
+
 fibers. ***p<0.01 vs WT. 
4.3.7 COMT reduced expression increases mRNA of GluN1 subunit expression  
Quantitative RT-PCR analysis showed an increase of GluN1 subunit mRNA levels in ileal LMMP 
preparations from COMT+/- mice compared to WT (+72±0.2%, p<0.01; Figure 4.34). These 
results indicate that COMT genetic modifications can impact in the glutamatergic transmission, 
leading to altered visceral pain perception, a frequent IBS comorbidity (Moloney et al., 2015). 
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Figure 4.34. Effect of COMT genetic reduction on NMDA receptor GluN1 subunit expression in murine 
ileal myenteric plexus. RT-PCR quantification of GluN1 transcripts performed in ileal LMMP preparations 
of COMT
+/-
and WT mice. Values (n=5) are expressed as mean ± SEM of the percentage variation of 
relative gene expression with respect to relative control (WT). The relative gene expression was 
determined by comparing 2
-ΔΔCt
 values normalized to β-actin. **p<0.01 vs WT.  
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5. DISCUSSION 
Homeostasis (oµoιoς [similar] and στάσις [status]), a characteristic common to all living 
organisms, is the natural tendency of an organ to reach a relative internal stability, in terms of 
chemical and physical properties, in response to changes of external conditions, in order to 
maintain a state of equilibrium over time. Internally, the intestinal homeostasis is under the 
control of the ENS, the second largest nervous system of the human body, which directly 
coordinates gastrointestinal functions including motility, secretion, mucosal immunity and 
visceral perception (Brun et al, 2013). Enteric neuronal circuitries display a considerable ability 
to adapt to a changing microenvironment, which comprises several cellular "players", including 
neurons, enteric glial cells, smooth muscle cells, interstitial cells of Cajal, and immune cells 
(Giaroni et al., 1999; Furness, 2012). This ‘second brain’ of the organism is indirectly exposed 
to the external luminal environment, which is mainly populated by the (non pathogenic) 
commensal microbiota, a ‘superorganism’ consisting of 10-time more microbes than host 
somatic cells. These microorganism forms a unique relationship with its host and then are 
crucial in guaranteeing intestinal epithelial integrity and barrier function, promoting gut 
development and maturation of the mucosal immune system (Shroff et al., 1995; Collins et al., 
2014). Gut microbiota is directly involved in modulating the development and function of the 
ENS supporting the view that changes in intestinal microbes composition, particularly in early 
life, induced by infections or antibiotics, perturb ENS integrity favoring the onset of 
gastrointestinal disorders (i.e. inflammatory bowel disease, IBD or irritable bowel syndrome, 
IBS; McVey Neufeld et al., 2013) Recently, the microbiota-gut-brain axis emerged as a key 
player also in the neurodevelopmental phases of the brain, indicating that events during initial 
colonization and microbiota development can impact general and mental health in later life 
(Diaz Heijtz et al., 2011; Borre et al., 2014). However, the molecular mechanisms by which the 
gut microbiota influences the development and organization of the ENS and consequently the 
CNS are still largely unknown. Host cells sense the presence of microorganisms throughout 
TLRs, an important subgroup of PRRs that are involved in the recognition and response to 
microbial components, derived from pathogens (PAMPs) or endogenous ligands derived from 
host cells damaged (DAMPs), and in detecting molecular component derived from commensal 
microorganisms. Thus, TLRs play a crucial role in the innate immunity protection from 
infection, in the control of tissue integrity and in the symbiosis between gut microbiota and 
the host (Kabouridis and Pachnis, 2015). Among TLRs, TLR2 is known to strengthen the 
intestinal epithelial cell barrier and prevent bacterial entry and inflammation (Rakoff-Nahoum 
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et al., 2004; Round et al., 2011) modulating immune response. Interestingly, TLR2 
polymorphisms have been identified in certain cases of IBD, although the relevance of this 
finding to the pathogenesis of Crohn’s disease or ulcerative colitis remains unclear (Pierik et 
al., 2006). Moreover, in the brain TLR2 is expressed in neurogenic areas of the brain. Rolls et al. 
demonstrated that TLR signaling play a crucial role in regulation of postnatal neuronal 
plasticity as it has been implicated in differentiation of neural stem/progenitor cells into 
neurons (Rolls et al., 2007). 
In the first part of this study we demonstrated the expression of TLR2 in the outer smooth 
muscular layer of small intestine. In particular, throughout immunohistochemical analysis 
performed on murine ileal frozen sections, we revealed the presence this receptor in the 
myenteric neurons of the ENS, as shown by the staining of TLR2 protein in neuronal cells that 
express the cytoskeletal protein peripherin. In addition, flow cytometry analysis on cells 
dissociated from LMMP of WT mice, identified the TLR2 expression on distinct cell types in the 
ileal muscle layer such as ECGs and smooth muscle cells, suggesting that the presence of TLR2 
in the ileal muscularis externa creates a mechanism for the gut luminal environment to 
communicate with the ENS without the interposition of immune or epithelial mucosal cells 
(Barajon et al., 2009). Given the existence of the gut-brain axis, the structural defects of 
regulatory proteins and neurofilaments expressed in the ENS appear to be phenotypic 
characteristics resembling those found in neurodegenerative disorders of the central and 
peripheral nervous system (Liem and Messing, 2009). Accordingly, we examined the impact of 
TLR2 absence on ENS development in adolescent TLR2-/-mice. A primary histological evaluation 
showed that in mice lacking TLR2 there are no signs of inflammation and that the gross 
morphology of the intestinal wall was maintained (Brun et al., 2013). Subsequently, whole 
mount immunohistochemistry performed on ileal LMMP evidenced anomalies in myenteric 
ganglia, indicated by lower HuC/D+ neuronal and S100β+ ECGs cells in TLR2-/- mice, associated 
with altered distribution of type III intermediate filament peripherin. The correct identification 
of neurons is critical to investigate and understand morphological and functional changes that 
may occur during health ad disease (Thacker et al., 2011; Desmet et al., 2014). HuC/D protein 
is used as a pan neuronal marker both in central and in the peripheral nervous system. It 
belongs to the family of Hu proteins, the human homologs of Drosophila melanogaster 
Embryonic Lethal Abnormal Vision (ELAV) proteins. Funtionally, HuC/D regulates the stability 
of specific mRNA (e.g VEGF, AChE, BDNF), modulating the precise and temporal expression of 
certain proteins (Desmet et al., 2014). The study of this protein allow the quantification of 
individual neurons and then is commonly used as a neuronal marker. However, because of its 
role in mRNA stabilization, HuC/D normally is located in the cytosol, but it can be also reach in 
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the nucleus throughout a specific transporter (Saito et al., 2004). Peripherin neuronal protein, 
which is expressed predominantly in the peripheral nervous system (PNS), is the major 
component found in inclusions of patients with amyotrophic lateral sclerosis (ALS). Moreover, 
peripherin expression is upregulated in ALS patients (Zhao and Liem, 2016). Similar to the CNS 
astrocytes, ECGs physiologically express the protein S100β, a small diffusible calcium-binding 
protein, that exerts either trophic or toxic effects depending on its levels in the extracellular 
milieu (Cirillo et al., 2011). Recently it has been demonstrated that aberrant expression and 
release of glial functional protein S100β correlate with the gut inflammatory status (Esposito 
et al., 2007; Cirillo et al., 2011). Our findings indicate that the absence of TLR2 induces 
anomalies in both structural and regulatory proteins of neurons and ECGs, affecting the 
neuronal and glial development in the ENS. Therefore, the absence of TLR2 signaling induces 
the presence of an underlying gut neuropathy (Brun et al., 2013). So the expression of TLR2 in 
the ENS could suggest a role in neuron survival, like TLR4, as demonstrated by the group of 
Anitha et al. (Anitha et al., 2012). The morphological abnormalities observed in the ENS of 
TLR2-/- mice were associated with impaired gut motor function. GI motility is defined by the 
movements of the digestive system, and the transit of the contents within it. The intestinal 
smooth muscle cells function as a syncytium, which is innervated by excitatory and inhibitory 
motor neurons. The correct equilibrium between contraction and relaxation is required for 
coordinate propulsive movements in the gut (Kunze and Furness, 1999). The main excitatory 
neurotransmitter in the ENS is acethylcoline, which act as a co-transmitter in the three broad 
classes of enteric neurons (motor neurons, interneurons and sensory neurons). Traditionally, 
cholinergic neurons were identified using a biochemical assay to detect AChE enzymatic 
activity (Johnson et al., 1995) at the site of active acethylcoline synthesis. AChE breaks down 
acethylcoline into choline and acetate once released from nerve terminals. AChE biochemical 
staining is used to demonstrate enlarged nerve trunks for the diagnosis of Hirschsprung’s 
disease (Dale et al., 1979; Moore and Johnson, 2005). In the gut NO is the messenger molecule 
responsible for regulating motility by acting as an inhibitory neurotransmitter and is produced 
by the enzyme NOS, which exists in three isoforms: neuronal nNOS, inducible NOS (iNOS) and 
endothelial NOS (eNOS). The three isoforms are structurally related but differ from each other 
in their genetic origin, anatomical distribution, ion dependence for activity, and 
pathophysiological functions, and are responsible of producing NO, a molecule with diverse 
physiological functions. TLR2-/- mice displayed anomalies in ENS neurochemical coding, as 
indicated by both the decrease of myenteric AchE+ positive nerve fibers and the reduction of 
the distribution and expression of neuronal nitric oxide synthase (nNOS). The morphological 
abnormalities in the ENS of TLR2-/- mice were associated with impaired small bowel function 
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evidenced by abnormal excitatory neurotransmission following in vitro electric field 
stimulation (EFS) and increased in vivo GI motility. Our findings indicate that TLR2 absence in 
ENS induces changes in the neurochemical coding of enteric neurons, accordingly affecting 
intestinal motility. Furthermore, we assessed whether TLR2-mediated functional anomalies 
were hematopoietic cell-independent. For this reason we generated bone-marrow chimera 
mice expressing TLR2 only in non-hematopoietic cells. Contractility experiments revealed no 
differences in neuromuscular function of WT mice given either WT or TLR2-/- bone marrow, as 
well as in that of TLR2-/- mice receiving either TLR2-/- or WT bone marrow, indicating that TLR2 
signaling in nonhematopoietic cells is a main contributor to ENS health (Brun et al., 2013). 
Functional or organic anomalies in the ENS could be ascribable to disturbances in neurotrophic 
factors signaling. GDNF elsewhere in the body is a pivotal postnatal neurotrophic factor, where 
it can be a pro-survival factor for midbrain dopaminergic neurons and is involved in axonal 
growth in the peripheral nervous system (Rappold and Tieu, 2010). It has been shown the 
primary role of GDNF in the ENS for proper its development and maintenance of the structural 
and functional integrity (Gershon, 2010; Zhang et al., 2010). Lack of GDNF signaling determines 
aganglionosis in children (Hirschsprung's disease; Gershon, 2010) and can leads to changes in 
ENS architecture and function during diabetic neuropathy (Anitha et al., 2006). In line with 
previous reports, intestinal smooth muscle cells during postnatal development appears to be 
the primary source of GDNF, which is required for neuronal cell survival, growth, and 
innervations of target tissues (Rodriguez et al., 2011). Moreover it is now known that TLRs are 
able to mediate CNS neurotrophic factors production (Bsibsi et al., 2006), thus we investigated 
the role of TLR2 signaling in regulating GDNF expression in small intestine. Our results 
demonstrated a deficit in the mRNA transcripts and immunoreactivity of GDNF in ileal muscle 
layers of mice lacking TLR2. Given that GDNF reverses hyperglycemia-induced neuronal 
apoptosis and loss of nNOS-containing neurons and also improves gastrointestinal motility in 
diabetic mice (Anitha et al., 2006) we tested the ability of recombinant GDNF (rGDNF) 
administration to rescue most of the defects in ENS architecture and function observed in 
TLR2-/- mice-. rGDNF supplementation of for 1 week significantly improved the contractile 
abnormalities in ileum segments from juvenile TLR2-/- mice, as shown by EFS-elicited response, 
which return to levels comparable to WT mice. Administration of rGDNF also rescues GI 
motility and moreover, prevented the loss of nitrergic neurons in myenteric ganglia, 
mantaining the number of nNOS+ neurons similar to those found in WT ileal specimens, as 
shown by confocal immunohistochemistry. Overall these data highlight that TLR2 is not merely 
a host immune sentinel but a dynamic guardian of ENS development and gut function (Brun et 
al., 2013).  
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Since it is necessary a proper expression and signaling of TLR2 in the small bowel to ensure the 
integrity of the ENS, this implicate that a proper commensal microbiota composition is needed. 
In mammalian development, the prenatal and postnatal periods are critical windows, since 
they are characterized by rapid changes in both neuronal and microbial organization (Borre et 
al., 2014). Shaping of the microbiota occurs in parallel with neurodevelopment and they have 
similar critical periods sensitive to damage (Wopereis et al., 2014). Importantly, childhood and 
adolescence are the most dynamic periods of change in relation to microbiota and nervous 
system development. The physicochemical conditions known to influence the composition of 
the intestinal microbiota include intestinal motility, pH, redox potential, nutrient supplies, host 
secretions (e.g. hydrochloric acid, digestive enzymes, bile and mucus), but in presence of 
infections or drugs can be seriously altered. In modern societies, widespread antibiotic 
administration is probably a major factor contributing to changes in the mucosal microbiota. 
Antibiotic administration, while facilitating clearance of targeted infections, also perturbs 
commensal microbial communities and decreases host resistance to antibiotic-resistant 
microbes (Ubeda and Pamer, 2012). In this regard, two recent studies showed that exposure to 
repeated antibiotic therapies in childhood leads to an increased risk of IBD in adulthood (Hviid 
et al., 2011; Kronman et al., 2012). Moreover, chronic treatment with antibiotics in mice 
during such critical periods can affect anxiety and cognitive behaviors as well as key 
neuromodulators of gut-brain communication increasing the risk of neurodevelopmental 
disorders and mental disorders (Borre et al., 2014; Desbonnet et al., 2015). In the second part 
of our study we assessed the effects of gut microbiota depletion on the structure and function 
of ENS in adolescent mice, by using a previously published protocol for manipulation of 
intestinal microbiota based on the administration of a cocktail of broad spectrum antibiotics, 
given to mice by oral gavage for 14 days (ABX mice; Reikvam et al., 2011; Brun et al., 2013). 
This protocol is based on the same composition of antibacterial agents as others have applied 
for ad libitum administration in drinking water. Thus, the choice of intragastric delivery is due 
to the fact that several published papers reported an incomplete depletion of the cultivable 
bacteria and an increased baseline morbidity and mortality of treated animals (Reikvam et al., 
2011). Ampicillin, vancomycin, neomycin and metronidazol display activity against the full 
spectrum of bacteria and, especially, dual activity against both Gram positive (ampicillin and 
vancomycin) and Gram negative (ampicillin and neomycin) aerobic and facultative strains, 
which is potentially important for preventing antibiotic resistance (Kollef, 2005). The depletion 
of gut microbiota through the use of broad spectrum antibiotics, orally administered, is a 
viable alternative to the use of mice bred in sterile environment from the birth. Germ-free 
animals may potentially be used for such comparative studies, but they need an expensive 
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germ-free facilities and they require special expertise and infrastructure (Reikvam et al., 2011). 
Compared with animals living in a conventional microbiological environment, germ-free 
animals display several phenotypic characteristics, such as an immature and underdeveloped 
lymphoid system (Smith et al., 2007). Exposure to the broad spectrum antibiotics solution 
determined a significant reduction of microbial population (Brun et al.,2013, data not shown) 
and produced in mice a marked enlargement in caecum, a phenotypic characteristic similar to 
those found in adult germ-free mice (Reikvam et al., 2011). We then evaluated the structure of 
ileal myenteric ganglia in gut microbiota-depleted mice. The confocal microscopy analysis 
performed on ileal frozen sections revealed several anomalies in the expression and 
distribution of typical neuronal and glial proteins in the ENS of ABX mice. Firstly, the 
immunoreactivity for HuC/D protein in myenteric plexus of ABX mice resulted significantly 
greater in microbiota-depleted mice compared to controls. We also found changes in the 
distribution of GFAP immunoreactivity that were asscociated with glial distorted cellular 
process. Interestingly, S100β immunoreactivity was found to be significantly increased in the 
ileal myenteric plexus of ABX mice (Caputi et al., 2015a). Damage to enteric glia have 
detrimental consequences for enteric neurons (Thacker et al., 2011). Therefore, the 
perturbation of gut microbiota composition compromise in an important manner the ENS 
architecture with effects on neuronal and glial survival. Changes in GFAP or S100β expression 
during glial cell differentiation, inflammation and injury, highlight that the levels of these 
proteins are associated to the functional state of ECGs (Cirillo et al., 2011). 
Antibiotic-induced microbiota depletion caused disturbances in ileal neuromuscular 
contractility, with a significant downward shift of the concentration-response curve to the non 
selective cholinergic receptor carbachol, along with a significant reduction to EFS at increasing 
frequencies (0-10 Hz), recognized by being mainly of neuronal cholinergic origin. Even the 
smooth muscle responsiveness was affected by antibiotic treatment as shown by the reduced 
Ileal contraction following high potassium-induced membrane depolarization. Given the strong 
impact of the main inhibitory neurotransmitter NO on intestine (Furness, 2012), intestinal 
contractility induced by nonadrenergic, noncholinergic nerve stimulation was assessed. EFS-
induced NANC stimulation at 10 Hz induced a marked relaxation, which resulted significantly 
enhanced in ileal preparations of ABX mice compared to controls. Moreover, pretreatment 
with the pan NOS inhibitor L-NAME partially abolished this response, suggesting that the 
depletion of gut microbiota can influence not only the nitrergic-mediated relaxation, but also 
the responses induced by other inhibitory neurotransmission (e.g. ATP or VIP), known to be 
involved in sustaining intestinal contractility function (Zizzo et al., 2003). The alterations of 
both excitatory and inhibitory pathway found in ABX mice can be ascribed to changes in ENS 
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neurochemical coding, as revealed by cholinergic fibers positive to AChE biochemical staining 
in ABX mice, which outnumber those of controls. Exposure to the ABX treatment did not affect 
the number of NADPH-d+ cells, however the immunoreactivity for nNOS resulted significantly 
increased in ABX mice (Caputi et al., 2015a). These abnormalities in the expression of both 
nNOS and S100β proteins, following microbiota manipulation, are indicative of the presence of 
a microinflammatory state causing the development of ENS neuropathy (Aubé et al., 2006; 
Cirillo et al., 2011). In several models of inflammatory bowel disease S100β upregulation has 
been shown to be accompanied by enhanced iNOS protein expression and consequent NO 
release (Cirillo et al., 2011), and this finding could explain the marked NO-mediated relaxation 
observed in ABX mice. On the other hand, the RNA-binding protein HuC/D is involved in 
regulating the expression of AChE during neuronal development in the CNS and the PNS 
(Deschenes-Furry et al., 2007), thus the increase of AChE+ fibers found in ABX mice may be 
related to enhanced expression of HuC/D protein. Consequently, the GI motility is dramatically 
affected by these ENS alterations. Antibiotic-mediated microbiota depletion determined a 
significant delay of GI transit, which was reflected in corresponding changes in stool frequency 
and water content, indicating a possible state of constipation and alteration of intestinal 
permeability as a result of antibiotic treatment (Caputi et al., 2015a). Changes in the 
composition of microbiota are common features in functional GI disorders, such as IBS, where 
dysbiosis is hypothesized to alter several neuronal mechanisms leading to visceral 
hypersensitivity (Daulatzai, 2014). In the ENS, glutamatergic neurotransmitter pathway is a 
recognized mechanism involved in amplifying nociceptive signals, principally through 
ionotropic AMPA and NMDA receptors activation (Kirchgessner, 2001). The role of these 
receptors in the intestine is currently unknown, but it is likely that they serve to integrate and 
amplify signals within the network, possibly resulting in altered gut motility, secretion, and 
enhanced visceral nociception (Petrenko et al., 2003). In particular, changes in NMDA receptor 
subunits in response to inflammation may have profound implications and could be involved in 
the pathophysiology of chronic visceral hypersensitivity seen in patients with post-infectious 
IBS and other chronic visceral pain disorders (Spiller, 2003; Zhou et al., 2009). Antibiotic 
treatment determined a significant increase of GluN1 subunit of NMDA receptor expression in 
ileal LMMP preparations, suggesting a link between gut-dysbiosis and visceral hypersensitivity 
mediated by the glutamatergic transmission in the enteric neuronal circuitries. Therefore, gut 
microbiota depletion in adolescence determines complex anomalies in ENS architecture, 
affecting excitatory and inhibitory neurotransmission leading to constipation and impaired gut 
neuromuscular contractility and visceral hypersensitivity with critical effects on gut function 
(Caputi et al., 2015a). As reported above, anomalies in neurotrophic factor signaling, such as 
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GDNF, can impact the correct neurodevelopment leading to morphofunctional abnormalities 
of ENS. Moreover TLR2 activation by bacterial components is required to stimulate production 
of GDNF in the gut (Brun et al., 2013; Brun et al., 2015). Antibiotic treatment strongly alters the 
microbiota composition creating a deficit in TLR-bacteria derived ligands. Consequently, the 
levels of GDNF in ileal muscular layer of ABX mice resulted significantly reduced. The 
administration of Pam3CSK4, a TLR1/TLR2 bacterial-derived ligand during the second week of 
ABX treatment, determined a significant increase of GDNF levels in ileal smooth muscle cells 
and partially ameliorated the defects in intestinal neuromuscular contraction of ABX mice 
confirming the role of the microbiota/TLR2 axis in ensuring the expression of neurotrophic 
factors that are required to maintain the functional organization of the mammalian ENS (Brun 
et al., 2013; Brun et al., 2015). These findings argue that development and maturation of the 
ENS depend on the complex interplay between immune- and neuro-regulators factors (Brun et 
al., 2013; Brun et al., 2015).  
Beside to the well-know role of TLRs in sensing molecular profiles derived from pathogens or 
commensal microorganisms, they also recognize endogenous molecular profiles derived from 
damaged cells (DAMPs), thus helping the repair of host tissue following inflammation. Oxidized 
phospholipids (OxPLs), an heterogeneous group of compounds that are generated during 
enzymatic and nonezymatic inflammatory processes and accumulate at sites of chronic 
inflammation, have been shown to modulate TLR-signaling in immune cells in both in vitro and 
in vivo. In particular, 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (OxPAPC) has 
been shown to inhibit only TLR2- and TLR4-MD2-dependent signaling pathways but not those 
activated by other TLRs, because of its binding with serum accessory proteins such as LBP and 
CD14 (Bochkov et al., 2002). This interaction competitively inhibits the binding of proper 
bacterial-derived ligand (such as LPS) to both TLR2 and TLR4 (Erridge et al., 2007). Thus, we 
evaluated the effect of OXPAPC inhibition of TLR2 and TLR4 on ENS integrity and intestinal 
motility. In WT mice P14 treated with OXPAPC for 1 week the receptor-mediated response to 
carbachol together with the neuromuscular contractions elicited by EFS were significantly 
increased. OXPAPC inhibition of TLR2 and TLR4 strongly impacted the ileal cholinergic 
excitatory neurotransmission, as demonstrated by changes in the distribution of the 
cholinergic AChE+ neurons in myenteric ganglia after the treatment. These findings underline 
the importance of a correct interaction between both TLR2/TLR4 and microbiota-derived 
ligands, which are required for preserving the integrity of the ENS excitatory neuronal 
network.  
In the last years, it has been highlighted the importance of the gut-brain axis, a bidirectional 
communication between the GI tract and the CNS, in connecting emotional and cognitive 
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centers of the brain with peripheral intestinal functions (Carabotti et al., 2015). A common 
human polymorphism of cathecol-O-metiltranferase (COMT), the val158met, which 
determines low activity of the enzyme with well recognized effects on CNS neurotransmission, 
has been associated with the visceral pain syndrome, a main feature in the pathophysiology of 
IBS. In this part of the research, we evaluated structural and functional anomalies in the ENS of 
an animal model of psychiatric disease, characterized by COMT genetically driven reduction in 
female adult mice. A preliminary assessment of ileal tissue from COMT+/- mice did not reveal 
any abnormal signals of illness, however H&E staining showed a marked increase in the 
thickness of outer ileal muscular layer. In the ENS of COMT+/- mice the ECGs appeared to be in 
an activate state, as demonstrated by changes in the distribution of GFAP and S100β 
immunoreactivities (Caputi et al, 2015b). The increased levels of catecholamines, due to the 
reduction of the COMT gene, resulted in accelerated GI motility and visceral hypersensitivity, 
due to increased levels of GluN1 subunit of NMDA receptor in the ENS. COMT+/- mice displayed 
an altered ENS neurochemical coding with lower number of AchE+ neurons and higher number 
of NADPH-d+ cells and these findings can affects intestinal contractility. Indeed, carbachol and 
EFS-elicited neuromuscular contractions were markedly reduced in ileal segments of COMT+/- 
mice, as well as muscle responsiveness elicited by KCl-induced depolarization (Caputi et al., 
2015b). On the other hand, EFS-induced NANC stimulation showed a marked relaxation in 
COMT+/- mice, which was partially abolished by pre-treatment with the pan-NOS inhibitor L-
NAME, suggesting that the disturbances of catecholaminergic transmission due to low activity 
of COMT can affect not only the nitrergic neurotransmission but also the involvement of other 
inhibitory signaling pathways (e.g. ATP, VIP, or dopamine), known to contribute in the 
regulation of intestinal contractility (Mulè and Serio, 2003; Zizzo et al., 2003; Li et al., 2006). 
Considering that a reduced genetic expression of COMT determines increased pain perception 
and muscular hypertrophy/hyperplasia, accelerated total gastrointestinal transit associated to 
altered ENS chemical coding and dysmotility, we can hypothesized that overall these effects 
are depending on the higher dopamine levels, which through D1 and D2 receptors exerts a net 
inhibitory effect in the GI tract (Zizzo et al., 2006; Li et al., 2006; Caputi et al.,2015b). 
In conclusion, our data demonstrate that TLR2 is not merely a host immune sensor, but a 
dynamic guardian of ENS integrity instrumental to preserve gut homeostasis. Most recently, 
several reports have expanded the role of gut microbiota to directly influencing gut−brain axis 
function, in view of the fact that alterations in microbiota are linked not just to gut 
inflammation, but also to changes in host behavior (Collins et al. 2012). Because stimuli 
delivered through TLRs, as shown by antibiotic-mediated microbiota depletion, can directly 
affect immunological responses and ENS integrity, it is evident that in the gut TLRs function lies 
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squarely at the crossroads of gut microbiota, epithelial barrier, and ENS, finely tuning 
beneficial and harmful insults. In the context of multifactorial pathologies, such as IBD and IBS, 
tuning innate immunity−ENS crosstalk might represent an attractive target for novel 
therapeutic strategies (Brun et al., 2013; Brun et al. 2014; Caputi et al., 2015a; Caputi et 
al.,2015b). 
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